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ABSTRACT
Overweight and obesity have been imposing $147 billion a year to the health care system
in the United States. Limited medications are available in the market with side effects. Surgical
treatments are second-line obesity treatments. Short chain fatty acids (SCFAs) produced from
the fermentable resistant starch improves the secretion of satiety hormones peptide YY (PYY)
and glucagon-like peptide 1 (GLP-1) from L-endocrine cells of cecum and colon.

We

hypothesized that consumption of fermentable non-digestible dietary fiber and bioactive
compounds will increase insulin sensitivity, reduce body fat, and improve healthspan in
Caenorhabditis elegans (C. elegans), and hyperglycemia (2% glucose) that may cause insulin
resistance and impair lipid metabolism will attenuate these effects. Wild type C. elegans N2 or
sir-2.1(ok434)IV, daf-16(mgDf50)I, and daf-16(mgDf50)I;daf-2(m65)III

mutants were used.

The control animals were fed with E. coli OP50. Experimental groups were fed with additional
treatments: butyrate (0.3mM, 0.6mM), sodium acetate (5mM, 50mM), sodium propionate (7mM),
or tributyrin (0.5mM, 3mM); PWB, oats or wheat bran (0.5%, 1.0%, or 3.0% w/v) with or
without additional 2% glucose. SCFAs increased the lifespan of N2 and daf-16(mgDf50)I, but
reduced lifespan in the daf-16/daf-2 deficient and sir-2.1(ok434)IV mutants. PWB or wheat bran
sustained the pharyngeal pumping rate (PPR) in N2, sir-2.1(ok434)IV, daf-16(mgDf50)I, and daf16(mgDf50)I;daf-2(m65)III. The N2, daf-16, or sir-2.1 mutant increased the PPR following oat
consumption. This increase persisted in the presence of glucose at a low dose in daf-16 or daf16/daf-2 mutant. The Nile red stained intestinal fat deposition (IFD) was reduced by butyrate
(0.3, 0.6mM), acetate (100mM), propionate (0.3mM), and tributyrin (0.1, 1mM) in N2; and was
increased in sir-2.1 mutant.

PWB reduced IFD in N2, sir-2.1 or daf-16 mutants.

Hyperglycaemia attenuated the effects on IFD in N2 or daf-16/daf-2 mutant.
x

Oat-feeding

decreased IFD in N2, and daf-16 or daf-16/daf-2 mutant with or without hyperglycaemia. Wheat
bran reduced IFD in N2, and in daf-16 or daf-16/daf-2 mutants without hyperglycemia, while
hyperglycemia increased IFD in sir-2.1(ok434)IV. In summary, PWB, oats, wheat bran, and
SCFAs reduced the IFD and improved the healthspan in C. elegans, and these effects were
mediated by the sir-2.1, daf-2, or daf-2/daf-16 pathways.

xi

CHAPTER 1: INTRODUCTION

1.1 General Introduction
Obesity are affecting more than one-third of the adults (34.9% or 78.6 million) and 17%
of the youth in the United States. Obesity is related to the increasing rate of chronic diseases
including cardiovascular diseases, type 2 diabetes, fatty liver diseases, atherosclerosis,
hypertension, insulin resistance, stroke, asthma, sleep apnea, osteoarthritis, neuro-degeneration,
gall-bladder disease and cancers (Hotamisligil et al., 1994). The increasing prevalence of obesity
associated diseases is responsible for the increased medical cost in the U.S. The estimated
annual medical cost of obesity in the U.S. was $147 billion in 2008; the medical costs of the
obese people were $1429 (estimated to be 42%) greater than normal weight people in 2006
(Finkelstein et al., 2009).
Anorectic agents and other anti-obesity drugs have been available for more than half a
century (Snow et al., 2005). The systematic side effects and safety concerns of obesity drugs,
however, have limited their clinical use. For example, The side effects of anti-obesity drugs
include: Exenatide causes headache, nausea, and vomiting (Fineman et al., 2004), Sibutramine
raises blood pressure, and Orlistat is associated with gastrointestinal in origin (Maahs et al.,
2006). Surgical treatments also have been used as treatment interventions (Snow et al., 2005,
Sinha et al., 2015, Zheng et al., 2010), but the high cost, potential risk, and weight regain have
limited the utilization of surgery (Cirocchi et al., 2013). Therefore, safe and effective obesity
treatments such as functional foods are in a growing demand. Functional foods provide medical
benefits beyond their essential function as nutrients (Bray and Greenway, 2007, Hotamisligil et
al., 1994). For example, the consumption of higher amounts of complex carbohydrate can lower
1

the prevalence of obesity, coronary heart disease, type 2diabetes, and cancers (Anderson, 2004,
Hauner et al., 2012). Dietary resistant starches (RS) present an emerging solution to obesity.
Gut bacteria have been demonstrated to ferment RS, high-amylose maize (Tachon et al., 2013).
Average daily consumption of dietary fiber in the U.S. is currently 3 to 10 g/day, 4 to 13
fold less than recommended (Goldring, 2004, Anderson and Akanji, 1991). RS commonly exists
in foods such as legumes, potato, and whole grains. RS can escape digestion by the digestive
enzymes in small intestine and can be fermented by some intestinal anaerobic bacteria in large
intestine as energy source for these bacteria and produce short-chain fatty acids (SCFAs, C2-C6)
which have been demonstrated as component in the maintenance of health (Keenan et al., 2007,
Fuentes-Zaragoza et al., 2010).
Dietary RS dilute energy density, reduce body fat, increase gut satiety hormones, elevate
fat oxidation and lower plasma cholesterol/triglyceride (Dethlefsen et al., 2007, Keenan et al.,
2006, Zhou et al., 2006). Feeding C. elegans with amylose starch significantly reduced the
fluorescent intensity of Nile red staining for the intestinal fat deposition (IFD) and increased the
locomotion of C. elegans (Zheng et al., 2010). The endogenous compounds filtered from the
microflora of cecal contents of mice fed high amylose starch showed similar trends to reduce the
fluorescent intensity of the Nile red positive IFD and to increase locomotion in C. elegans.
Keenan et al. has demonstrated that RS feeding to rodents reduces abdominal fat significantly
(Keenan et al., 2007). Zhou et al. has demonstrated that total glucagon-like peptide 1 (GLP-1)
and total peptide-YY (PYY) in rats fed a RS diet were significantly increased compared with
controls; Plasma PYY and gene transcription for PYY in the cecum from rats were significantly
increased (Zhou et al., 2008). RS can also augment food digestion and GI motility, stimulate the
growth of beneficial microorganisms in the colon and maintain bowel health (Burnell et al., 2005,
2

Zheng et al., 2010). Furthermore, RS promote insulin sensitivity, boost mitochondrial function,
and enhance hosts’ health (Zhou et al., 2008, Tachon et al., 2013, Keenan et al., 2013, Dethlefsen
et al., 2007, Flint, 2012, Forsberg et al., 2014, Sekirov et al., 2010).
Endogenous SCFAs are major products from the fermentation of RS by intestinal
anaerobic bacteria. The endogenous SCFAs produced mainly include acetate, propionate, and
butyrate (Haarman and Knol, 2006, Duncan et al., 2003, Louis et al., 2007, Dethlefsen et al.,
2007, Sekirov et al., 2010). These SCFAs contribute to normal large-bowel functions including
the stimulation of fluid, the absorption of electrolyte and the modulation of muscular contraction
by the perfusion of visceral circulation (Topping and Clifton, 2001). SCFAs produced by gut
bacteria from the fermentable RS also increase the secretion of satiety hormones PYY and GLP1 from L-endocrine cells of the cecum and colon (Keenan et al., 2013, Zheng et al., 2008).
Barley is the fourth most important cultivated foodstuff. It contains 62-77 % starch (w/w)
which is composed of 25-35% amylose starch with 3-5% RS3 and β-glucan (Asare et al., 2011,
Vasanthan and Bhatty, 1998), a mixture that provides a distinctive amylose–amylopectin
interaction (Tang et al., 2001, Lifschitz et al., 2002, Behall et al., 2005, Rendell et al., 2005,
Dongowski et al., 2002). Barley also contains high levels of functional lipids, such as, total
phytosterols (1.2-9.6% of barley oil) and total tocotrienols (0.3-0.6% of barley oil) which are 612 fold higher than in palm oil (0.05%) and 4-8 folds higher than in rice bran oil (0.08%)
(Moreau et al., 2007). Barley also provides vitamins, trace minerals, and bioactive compounds
(Inglett et al., 2011, Cui and Wang, 2009). In addition, there are many phenolic compounds in
barley, such as benzoic and cinnamic acid derivatives, proanthocyanidins, quinones, flavonols,
chalcones, flavones, flavanones, and amino phenolic compounds (Holtekjølen et al., 2008,
Verardo et al., 2008). These phenolic compounds in barley serve as natural antioxidants with
3

antiradical and antiproliferative potentials for disease prevention and health promotion
(Madhujith and Shahidi, 2007).
The nematode Caenorhabditis elegans (C. elegans) is a multicellular eukaryote with
small size and short lifespan. C. elegans conserves 65% of the genes associated with human
disease and 35% of genes homologue to human (Villegas et al., 2008). The C. elegans model is
considered as an convenient organism to screen different sources of prebiotics and
pharmaceutical compounds and study human diseases or study of aging and test of the
therapeutic compounds that may curtail aging (Zheng et al., 2010, Finley et al., 2013, Zheng et
al., 2014, Zheng and Greenway, 2012). C. elegans is a model organism that is less expensive,
more time-efficient, and a convenient option for initial high-throughput screening and detailed
mechanism research (Villegas et al., 2008).
Insulin/Insulin-like growth factor Signaling (IIS) pathway is a primary mechanism for
controlling metabolic physiology not only in humans, but also in C. elegans (Van Dyke and
McCarthy, 2002). Many components of the IIS pathway are conserved from nematodes to
humans (Barbieri et al., 2003, Zheng and Greenway, 2012). Reduction in the activities of the
components of the IIS pathway leads to the activation of a series of genes involved in lifespan
control, stress tolerance and protein misfolding suppression, collectively resulting in life-span
extension (Kenyon, 2010, Lin et al., 1997). dauer formation-2 gene (daf-2) C. elegans mutants
cause fat accumulation and glycogen production in adult (Burnell et al., 2005, Kimura et al.,
1997). daf-16 is critical in mediating the downstream insulin signaling pathways and is the
major target of the daf-2 pathway, a homolog of the insulin and insulin-like growth factor (IGF)
receptors (Zheng and Greenway, 2012, Rizki et al., 2011, Von Stetina et al., 2007). ‘Aging’ has
been reported to be related with the downstream effects of IIS pathway (Benedetti et al., 2008).
4

C. elegans has both an aerobic and an anaerobic metabolism, and can survive under a
hypoxic condition (Burnell et al., 2005). Oxygen or “hypoxia gradient”-oxygen deprivation
diffuses bidirectionally between the intestinal tract and the external environment (Burnell et al.,
2005).

John Finley, et al in 2013 have demonstrated that high amylose maize RS2, legume

(Finley et al., 2013), and the endogenous fermentation products from RS reduced the fluorescent
intensity of the Nile red positive intestinal fat deposition (IFD) in C. elegans in vivo (Zheng et al.,
2010, Zheng and Greenway, 2012, Dethlefsen et al., 2007, Flint, 2012, Finley et al., 2013). Our
data suggest a possibility that the anaerobic bacteria in the C. elegans intestinal tract could
ferment dietary fibers. Direct identification of C. elegans intestinal microbiota has not been
reported. We hypothesize that feeding fermentable dietary fibers to C. elegans should closely
resemble the effect of colonic fermentation products by the intestinal anaerobic microbiota in the
large intestine in rodents or in humans. Likewise, a potential relationship of microbiome with C.
elegans has been proposed (Cabreiro and Gems, 2013).
The objectives of this study were to determine the effects of consumption of
Prowashonupana barley (PWB), Oats, or wheat bran byproduct which are rich in fermentable
dietary fibers and other bioactive components on the IFD, lifespan, insulin resistance, and
hyperglycemia-impaired lipid metabolism using high through-put C. elegans model. In addition,
a pilot study was performed to investigate whether PWB increases the intestinal anaerobic
microbiota in C. elegans.
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CHAPTER 2: REVIEW OF LITERATURE
2.1 Background of obesity
2.1.1 Prevalence of obesity
Obesity is an accumulation of excessive body fat. A popular acceptable definition of
obesity is the body mass index (BMI), which is the body weight in kilogram divided by the
square of body height in meter, exceeding 30kg/m2. Overweight is defined as a BMI of 25 or
higher. Extreme obesity is BMI more than 40 kg/m2. The prevalence disorders of obesity have
been increasing at a rapid rate in both developed and developing countries.

The obese

population is affecting more than one-third of the United States adults aged 18 years and over
(34.9% or 78.6 million) and 17% of youth aged 0-17 (Zheng and Greenway, 2012, Ogden et al.,
2014). The prevalence of obesity distribution map showed that no state in the U.S. has a
prevalence of obesity less than 20% (Figure 1). The West had the lowest prevalence of obesity
(24.9%), followed by the Northeast (26.5%), the Midwest (30.1%), and the South (30.2%). The
States of Mississippi and West Virginia had more than 35% of obesity prevalence.

The

Louisiana’s adult obesity rate in 2014 is 34.9 percent as the fourth highest rate in the nation
(Health, 2015). The increasing prevalence of obesity is responsible for the increased medical
cost in the U.S. The estimated annual medical cost of obesity in the U.S. was $147 billion in
2008; the medical costs of the obese people were estimated to be $1,429 (42%) greater than
normal weight people in 2006 (Finkelstein et al., 2009). Obesity predisposes to diabetes and/or
other health care costs to an even greater extent (Scheen, 2000).
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Figure 1 Prevalence of Self-Reported Obesity among U.S. Adults by State and Territory, BRFSS,
2013. Source: Behavioral Risk Factor Surveillance Systems, CDC.

2.1.2 Obesity related health issues
Obesity is associated with an increased risk for developing diabetes, cardiovascular
diseases, stroke, osteoarthritis, liver and gallbladder disease, sleep apnea and respiratory
problems, and certain types of cancer (WHO, 2000, Must et al., 1999). Obesity also induce to
hypertension, hyperlipidemia and hyperinsulinemia/insulin resistance (Kotsis et al., 2010).
Additionally, obesity is correlated to impaired glucose tolerance, high levels of circulating
insulin, and reduced insulin sensitivity. Obesity and insulin resistance are recognized as the
leading causes of type 2 diabetes and the obese people have higher risk factors of insulin
resistance than normal weight people (Kadowaki et al., 2003). Moreover, obese people display
higher blood pressure levels than normal weight individuals even in the normotensive range; the
obesity and hypertensions increase the probabilities of coronary diseases (Kotsis et al., 2010). In
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addition, excess weight has a positive relationship with mortality which may differ among racial
and ethnic groups (Must et al., 1999). The health risk increase is associated with a relatively
small body weight gain, even not marked as obese (Health, 1998).
2.1.3 Causes of obesity
Obesity is a complex and incompletely understood chronic disease. Varieties of factors
play roles in obesity including behavior, society, environment, metabolism, and genetic factors.
One of the commonly acceptable reasons for obesity is energy imbalance that is energy or calorie
intake higher than energy expenditure that a person uses to breathe, circulate blood, digest food,
and be physically active (Danforth, 1985). The excess energy will be accumulated as fat or
glycogen in the body. Overweight and obesity happen over time when the calories intake is
always more than the expenditure. Environment and behavior factors include lack of physical
activities, lack of healthy foods, oversized food portions, smoking, and stress associate with
overweight and obesity (Health, 1998). Over the last 50 years, there has been a trend of
increased intake of calorically dense foods that are high in fat, sugars, and salt but low in
vitamins, minerals, and other micronutrients. There also has been a simultaneous trend of
decreasing physical activity due to the increasingly sedentary nature of many forms of work,
changing modes of transportation, and increasing urbanization (French et al., 2001, Kumanyika,
2001). In addition, family history also influences the amount of fat stored in body because
family members may share the similar habits, foods, and similar physical activities. Genes play
an important role in the development of obesity; genes determine that some races have higher
risk than others. Hormone problems such as underactive thyroid (hypothyroidism), Cushing’s
syndrome, and polycystic ovarian syndrome (PCOS) may also cause overweigh/obesity (Health,
1998).
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2.1.4 Obesity treatments
Obesity is an epidemic chronic disease that requires effective prevention and
management in long-term strategies.

Although pharmaceutical, medical, and surgical

interventions to treat obesity are available, the practical use of these treatments remain rare
(Finkelstein et al., 2009). A reduced energy intake through reduced dietary energy density,
increased energy expenditure through exercise, lifestyle modification, anorectic agents, other
drugs to treat obesity, and bariatric surgery have all been used as treatment interventions (Wirth
et al., 2014, Zheng et al., 2010). Anti-obesity pharmaceuticals have limited efficacy on weight
loss and the safety concern also curtailed the usage. Two obesity drugs including sibutramine
and orlistat have been approved by FDA for long-term use (Bray and Greenway, 2007, Zheng et
al., 2010). However, both of them cause side effects. Sibutramine may cause blood pressure
increase, dizziness or blurred vision; back pain, dry mouth, headache, nausea, nervousness, etc.
Orlistat is associated with embarrassing gastrointestinal side effects such as anal leakage and
incontinence. Phentermine is approved as an appetite suppressant to reduce weight for shortterm use. The adverse effects of phentermine include nervousness, vomiting, headache, etc.
(Nelson and Gehlert, 2006). Lorcaserin that is another weight-loss drug has side effect of
causing headache, dizziness, nausea, anxiety, and pain in muscles (Rankin and Wittert, 2015,
Halpern and Halpern, 2015). Liraglutide that is a long-acting glucagon-like peptide-1 receptor
agonist has side effects including headache, dizziness, nausea, and tired feeling (Rankin and
Wittert, 2015, van Velsen et al., 2014). Another medicine used to manage weight in obese or
overweight is Contrave that contains a combination of bupropion and naltrexone (Drugs.com,
2015).

Side effects of this medicine is blurred vision, dizziness, nervousness, headache,
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tiredness, and irritability (Drugs.com).

Other anti-obesity drugs in the U.S. such as

benzphetamine, diethylpropion, and phendimetrazine are also associated with side effects
(Hampp et al., 2013, Drugs.com, 2015, Cerner Multum, 2013). The weight loss effects of these
anti-obesity treatment groups are modest, which reduced body weight less than 5% compared to
the placebo groups (Li et al., 2005). Therefore, anti-obesity drugs available in the market are not
efficient and safe strategies for treating and preventing obesity.
Extreme obese patients (BMI of 40 kg/m2 or greater) with obesity-related comorbid
conditions could consider surgical intervention. Comorbid conditions include hypertension,
impaired glucose tolerance, diabetes mellitus, hyperlipidemia, and obstructive sleep apnea
(Khaodhiar et al., 1999). Lifestyle modification including diet and behavior should always be
recommended to all the obese patients. Before surgery, patients should undergo an assessment
that includes metabolic, cardiovascular, psychosocial, and dietary details (Wirth et al., 2014).
Early mortality rates for Roux-en-Y gastric bypass (RYGB) range from 0.3% to 1.9% and an
evident learning curve for the operator (Snow et al., 2005). Additionally, the cost of such
surgeries cannot be covered by insurance. Commonly used surgical methods include sleeve
gastrectomy, gastric banding, and gastric bypass (Torres and Rubio, 2011). After bariatric
surgery, lifestyle modification is required for weight management.
2.1.5 Treat obesity by modified diet
Obesity is largely preventable through lifestyle modifications which enhance human and
animal insulin sensitivity, reduce visceral adiposity, lower triglyceride levels, and reduce the risk
of impaired glucose tolerance (Mann, 2000). The lifestyle modifications include reducing the
saturated fatty acid and carbohydrate intake, increasing the consumptions of polyunsaturated
fatty acid, fruits, vegetables, whole-grain, increasing physical activity, and decreased sedentary
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activity (Mann, 2000, Kamath et al., 2008). Energy dilution in the diet with fruits, vegetables,
and whole grains is considered an suggested approach to manage of body weight because the
ample amounts of fiber and water in these food products dilute the energy content per volume of
food (USDA, 2010, Darmon et al., 2004). Weight loss in overweight and obese people reduces
the risk of diabetes and coronary heart disease, reduces blood pressure and serum triglycerides,
increases high-density lipoprotein (HDL)-cholesterol, and generally results in the total serum
cholesterol reduction and low-density lipoprotein (LDL)-cholesterol (Health, 1998).
Plant source foods or their carbohydrate components have functions in the management
and prevention of non-infectious chronic illnesses. The consumption of higher amounts of
complex carbohydrate such as whole-grain foods lowers the prevalence of obesity, coronary
heart disease, type 2 diabetes, and certain cancers (Anderson, 2004, Hauner et al., 2012). Wholegrain foods are high in RS and dietary fiber, and they are less energy dense compared with
refined grain foods. Whole grain foods have components that resist intestinal digestive enzymes,
which helps to explain their effectiveness in increasing fecal bulk, an important component of
their laxative action (Topping and Clifton, 2001). Previous studies have reported a negative
relationship between fiber consumption and the risk of obesity and diabetes (Haenen et al., 2013)
since consumption of dietary fiber decreases the accumulation of fat mass, increases insulin
sensitivity, and it can enhance feelings of satiety (Haenen et al., 2013). Whole grain cereals
contain nutrients and bioactive compounds that have health promoting benefits (Rebello et al.,
2014). Additionally, epidemiological studies demonstrated that cereal fiber and whole grain
consumption lower the risk factors such as inflammation, insulin resistance, elevated blood
pressure, and dyslipidemia, of chronic diseases including obesity, diabetes, and CVD (Rebello et
al., 2014). Bioactive compounds from plants, animals, and marine foods have attracted much
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attention because of their potential benefits to human health including anti-obesity, antiinflammation, and anti-oxidant properties (Wang et al., 2008, Jayaprakasam et al., 2005). These
compounds could be free radical scavengers and that act as potential chemo preventive agents
(Rebello et al., 2014, Fardet et al., 2008). Therefore, the consumption of compounds containing
RS and dietary fibers may play a positive role in weight management.
2.2 Health benefits of resistant starch and dietary fiber
2.2.1 Resistant starch
Starch is classified as rapidly digestible starch (RDS), slowly digestible starch (SDS) and
RS in order to characterize its nutritional property. The RS is a form of dietary fiber. RS exists
in several foods such as legumes, potato, and whole grains. RS can escape from digestion by the
digestive enzymes in the small intestine and can be fermented by gut microbiota in large
intestine as energy source for these bacteria and produce SCFAs (Keenan et al., 2007, FuentesZaragoza et al., 2010). A Dietary Reference Intakes Committee has recommended more research
into dietary energy dilution for weight control and weight loss (Health, 1998, Health, 2015).
Adding RS to the diet has the effects of diluting dietary energy density and a bulking effect
similar to non-fermentable fiber. The RS from whole-grain has shown increased post-prandial
satiety in humans (Anderson et al., 2010). Four main types of RS have been identified based on
the structure or source (Murphy et al., 2008): RS type 1 (RS1) bound by indigestible plant cell
walls; found in whole-grains such as beans, grains, and seeds. RS type 2 (RS2) that is resistant to
digestion in the raw state and under low heat treatment due to its high amylose content. This
type of RS is found in potatoes, bananas, plantains, and high amylose corn. RS2 becomes
accessible upon high heating that destroy the starch granulate. RS type 3 (RS3) forms from
retrograded amylose and amylopectin during food processing. When some starches are cooked,
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cooling them (fridge or freezer) changes the structure and makes it more resistant to digestion;
found in cooked and cooled potatoes, grains, bread, cornflakes, and beans. RS type 4 (RS4)
doesn’t occur naturally and has been chemically modified. RS has a low calorific (8 kJ/g) value
compared with fully digestible starch (15 kJ/g) (Fuentes-Zaragoza et al., 2010). Fermentable RS
dilute the dietary energy in the diet and increases energy expenditure and plasma levels of PYY,
increases GLP-1, and attenuates body fat accretion in rodent models (Keenan et al., 2006, Zhou
et al., 2006). RS also provides health benefits in reducing body fat in rodents and humans (Zhou
et al., 2006). It may lower plasma lipid levels and triglyceride concentration, especially plasma
cholesterol, by delaying gastric emptying, thereby limiting hepatic lipogenesis owing to less
glucose as substrate and less insulin as an activator (Higgins et al., 2004). RS has been shown to
promote colon function by alleviating infectious diarrhea and promoting colonic mineral
absorption due to the interactions between RS and the microflora (Keenan et al., 2013). RS, a
prebiotic, intakes correlate negatively with colorectal cancer risk (Topping and Clifton, 2001).
High amylose Maize starch is fermented by Ovariectomized (OVX) rats with increased bacteria
levels, especially promotes the survival of Lactobacillus species (Keenan et al., 2013).
2.2.2 β-glucans
β-glucan is a major component of water soluble cereal fiber (Figure 2). Soluble oat fiber,
oat β-glucan, consists mainly of linear polysaccharide (1→3), (1→4)-β-D-glucan (Zhang et al.,
2012). The (1→3)-link prevents close packing of the molecule and makes the molecule partly
soluble in water (Morgan, 2000). The molecular weight of β-glucan varies between 50 and 3000
kDa. β-glucan usually comprises 2-8% (dry weight) of the oat whole grain. Barley grains rich in
β-glucan provides an excellent source of soluble dietary fiber for attenuating blood glucose and
reducing low-density lipoprotein cholesterols (LDL). Barley β-glucan is a functional ingredient
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implicated to lower glycemic response, plasma cholesterol and food intake. Health benefits
associated with β-glucan might depend on their polyphenol and antioxidant contents that vary
with the method of preparation and purity (Zhang et al., 2012).
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Figure 2 Structure of β-D-glucan.
2.2.3 SCFAs and gut microbiota
The gastro-intestinal tract harbors a vast majority of microbiota in human and other
mammals’ cecum and colon that count for an estimated mass of 250–750 g of digestion and
equal to at least 1010 to 1011 cfu/g wet weight (Topping and Clifton, 2001). More than 50 genera
and over 300-1000 species of bacteria have been identified in human feces (Hill, 1995, Nagpal et
al., 2015). The dominant anaerobic organisms include Bacteroides, Bifidobacteria, Eubacteria,
Streptococci, and Lactobacilli, while others, such as Enterobacteria, may also be found (Hill,
1995, Topping and Clifton, 2001).

Some bacteria grown on intermediate products of

fermentation such as H2, lactate, succinate, formate, and ethanol, and convert them to the end
products such as SCFAs (Cummings et al., 1987). Some other bacteria convert CO2 to acetate or
methane (CH4). Microbes in the digestive system have a homeostatic symbiosis relationship in
which the host provides a stable environment with nutrients and the microbes provide benefits as
well to the host (Leser and Molbak, 2009). Gut microbiota are directly related to mechanisms
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including defense against pathogens, synthesis of vitamins, fermentation of dietary fibers and
dietary proteins; priming the immune system early in life; and stimulating the gut motility (Leser
and Molbak, 2009, Topping and Clifton, 2001). The colonic microflora are affected by the gross
nutritional shifts, aging, or variations in food intake. Aged people have relatively lower amounts
of Bifidobacteria but the count for Escherichia coli (E. coli), Streptococci, and Clostridia are
increased (Mitsuoka, 1996).
The SCFAs including acetate (C2), propionate (C3), and butyrate (C4) are the major
fermented metabolic products of dietary fiber and RS in the human gastrointestinal (GI) tract
(Vinolo et al., 2011). Animal studies, principally with rats and pigs, have shown that large
bowel SCFAs are increased by the provision of fermentable carbohydrates (Keenan et al., 2007,
Keenan et al., 2006). Various anaerobic bacterial populations are involved in the production of
SCFAs and conversion of polysaccharides, oligosaccharides, and disaccharides to their
constituent sugars.

This fermentation also provides energy for microbial growth and

maintenance and also metabolic end products such as SCFAs, H2, lactate, succinate, formate, and
ethanol (Topping and Clifton, 2001). Intestinal microbial communities hydrolyze non-digestible
plant polysaccharides such as lignin, hemicelluloses, pectin, cellulose, and RS into SCFAs which
are readily absorbed and used as energy sources by colonocytes, and also by other tissues
including liver and muscle (Vinolo et al., 2011).
SCFAs have been demonstrated for their role in colonic health and reducing the risk of
metabolic diseases, including irritable bowel syndrome, inflammatory bowel disease, obesity,
cardiovascular disease, and cancer (Reimer et al., 2014, Vinolo et al., 2011). These fatty acids as
anti-inflammatory agents affect the function of leukocytes, inhibit stimuli-induced expression of
adhesion molecules, chemokine production and consequently suppress monocyte/macrophage
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and neutrophil recruitment (Vinolo et al., 2011). SCFAs produced by gut bacteria from the
fermentable RS increase secretion of satiety hormones PYY and GLP-1 from epithelial cells of
the cecum and colon (Keenan et al., 2013, Zhou et al., 2008, Zheng et al., 2008).
Increasing lines of evidence support the hypothesis that the total beneficial anaerobic
bacterial population in fecal samples directly associates with prebiotics intake as an energy
source, produces fermentation products, and has the capability of controlling type 2 diabetes,
obesity, and aging (Turnbaugh et al., 2009, Van der Meulen et al., 2006, Flint, 2012).
Meanwhile, prebiotics alter the composition and population of intestinal microbiota by
enhancing the growth of beneficial bacteria (Turnbaugh et al., 2006), which regulate host
metabolism by the xenobiotic compounds perceived in the intestine (Cabreiro and Gems, 2013,
Shen et al., 2009). Colonic anaerobic microbiota Bifidobacteria, Bacteroides, Lactobacilli,
Clostridium cluster IV, and Clostridium Cluster XIVa/XIVab are necessary for the fermentation
of dietary fibers in humans or rodents (Keenan et al., 2006). Clostridium cluster IV primers for
PCR include subgroups that represent a mixture of genera including Clostridium, Eubacterium,
and Ruminococcus (Van Dyke and McCarthy, 2002). Clostridium cluster XIVa and XIVab
comprises more than 20 clostridial species (Matsuki et al., 2002, Van Dyke and McCarthy, 2002).
Bacteroidetes primers are used to enumerate the Bacteroides group including Prevotella and
Porphyromonas spp. Bacteroides spp. are anaerobic Gram-negative bacillus bacteria (Duncan et
al., 2003, Bartosch et al., 2004). Bifidobacteria primers are used to identify Bifidobacterium spp.
which are classified under phylum Actinobacteria (Bartosch et al., 2004), a strictly Grampositive anaerobic branched rod producing lactic and acetic acid but not CO2 (Van der Meulen et
al., 2006).

Lactobacillus primers can detect a genus of bacteria under phylum Firmicutes

(Haarman and Knol, 2006), which consume wide varieties of carbohydrate as fermentation
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energy source and grow under aerobic conditions or intestinal anaerobic conditions (Van Dyke
and McCarthy, 2002, Silva et al., 1987).
2.2.4 SCFAs
2.2.4.1 Butyrate
The health benefits of butyrate have attracted the most attention from investigators.
Butyrate is a major energy source for epithelial cells of colonic mucosa that stimulate cell
proliferation (Scheppach et al., 2001). Sodium butyrate is the sodium salt of butyric acid, which
is a four carbon normal fatty acid and is a natural metabolite in many organisms including
bacteria populating the gastrointestinal tract.

The health benefits of butyrate include the

prevention and inhibition of colon carcinogenesis, protection against mucosal oxidative stress,
and strengthening of the colonic defense barrier; butyrate also has anti-inflammatory properties
(Hamer et al., 2008). Studies in vitro demonstrated that exposure of many tumor cell lines to
butyrate leads to anticarcinogenic effects by induction of apoptosis, inhibition of proliferation
and promotion of a more differentiated phenotype (Hamer et al., 2008). The anti-inflammatory
effect of butyrate is demonstrated by the suppression of nuclear factor kappa-B (NF-κB) and
inhibition of HDAC (Andoh et al., 1999, Place et al., 2005). NF-κB is a transcription factor that
controls the expression of genes encoding proinflammatory cytokines, chemokins, inducible
inflammatory enzymes (Jobin and Sartor, 2000). Moreover, butyrate may affect DNA repair
systems and levels of enzymatic or non-enzymatic antioxidant systems (Hamer et al., 2008).
Dietary RS increase PYY and GLP-1 satiety gene and hormone expression which are also
associated with increased butyrate levels in the cecum in rats (Keenan et al., 2006).
2.2.4.2 Acetate
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Acetate is the most abundant SCFA product by the colonic microflora; it is
approximately 60-75% of the total SCFAs in feces; it is quickly absorbed soon after production
and transported to the liver (Louis et al., 2007). Acetate is essential for cholesterol synthesis in
the body (Hijova and Chmelarova, 2007). The major benefit of acetate is that it acts as an energy
substrate for muscles as acetate reaches the systemic circulation (the portion of the
cardiovascular system which carries oxygenated blood away from the heart, to the body, and
returns deoxygenated blood back to the heart) (Kiviluoma et al., 1988). Acetate has been shown
to suppress harmful bacteria growth (Araya-Kojima et al., 1995).
2.2.4.3 Propionate
Propionate has previously been indicated as another health-promoting metabolite being
produced by the gut microbiota fermented RS in the large intestine. Propionate has the potential
to reduce cholesterol concentrations in blood (Hosseini et al., 2011). Propionate is metabolized
by the liver and used for gluconeogenesis, whereas acetate is a substrate for cholesterol synthesis
and lipogenesis (Haenen et al., 2013).
2.3 Prowashonupana barley
Barley is a healthy cereal grain with a rich nutlike flavor.

Barley is one of the

domesticated grains since the ancient time. Barley has been widely distributed in more than 100
countries in the world. Barley has been used in animal feed, fish feed, beverages, alcohol, and
foods. Barley is nutritious and popular health food. Hullness barley is a form of domesticated
barley. Barley has attracted much attention for the health promoting properties.
Table 1 Average nutrient content of hullness barley, oat groats, and Prowashonupana barley.
Nutrient,%

Hullness barley

Oat groats

Prowash barley

Protein
Fat

13
3

15
6

20
7

18

Starch
60
59
21
LMW sugars
1
1
7
Total fiber
13
10
30
β-Glucan
5
5
15
Prowashonupana barley (Hordeum vulgare) is a waxy, hullness, shrunken-endosperm,
short awn barley with low glycemic index, low starch, high fiber, high protein and relatively low
calories (Rendell et al., 2005). The Prowashonupana barley has 30% dietary fiber and 21%
starch, which are 2~3 times the amount of fiber and approximately half the amount of starch
compared with other common cereal grains (Table 1). Approximately half of the dietary fiber is
β-glucan.

Hallfrisch et al. indicated that hydrocolloids (β-glucan) extracted from

Prowashonupana were as effective in reducing glucose and insulin responses in non-diabetics as
an oat extract, barley or oats (Hallfrisch J, 2003). Products containing barley flour improve
glycemic control in type II diabetic subjects, reduce glycemic index (GI) values (GI=28 to 39),
and lower absorption of energy nutrients (Lifschitz et al., 2002, Kim et al., 2011, Hole et al.,
2012). Barley also provides vitamins, trace minerals, and bioactive compounds (Inglett et al.,
2011, Cui and Wang, 2009). There are many phenolic compounds in barley, such as benzoic and
cinnamic acid derivatives, proanthocyanidins, quinones, flavonols, chalcones, flavones,
flavanones, and amino phenolic compounds (Holtekjølen et al., 2008, Verardo et al., 2008).
These phenolic compounds serve as natural antioxidants with antiradical and antiproliferative
potentials for disease prevention and health promotion (Madhujith and Shahidi, 2007).
Prowashonupana barley can also be used in a variety of foods such as hot cereals, cookies,
crackers, breads, tortillas, granola bars, fruit-filled cereal bars, extruded snacks, and pastas. It
can enhance the flavor, texture, appearance and nutritional compositions of these foods.
2.4 Oats
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A species of cereal grain, oat (Avena Sativa), is mainly used as oatmeal for human
consumption as well as livestock feed. Oat has been demonstrated as a health promoting food
that is able to attenuate blood postprandial glycemic and insulinemic responses, to lower blood
total cholesterol and low-density lipoprotein (LDL) cholesterol, and to improve high-density
lipoprotein (HDL) cholesterol and blood lipid profiles as well as to maintain body weight (Zhang
et al., 2012). Oat is also capable of modifying immune response and reducing the risk of colon
cancer (Mälkki and Virtanen, 2001).

It is also known for its effect of satiety, retarding

absorption of nutrients, as well as a deterrent of various disorders of the gastrointestinal tract
(Mälkki and Virtanen, 2001).

The oats high in soluble fiber content, low in saturated fat and

cholesterol may reduce the risk of heart disease (Table 2) (Zhang et al., 2012). The main soluble
fiber components in oat is a class of polysaccharides known as beta-D-glucan in a structure of
(1→3), (1→4)-β-D-glucan, while the main glucan in mushrooms and yeasts is (1→3), (1→6)-βD-glucan (Zhang et al., 2012). The effects of oat on GI tract are due to both soluble and
insoluble fibers because soluble fiber has high swelling and water-binding ability, and as a
substrate in colon fermentations and insoluble fiber has bulking effect (Mälkki and Virtanen,
2001).
Polyphenols have various biological functions, such as antioxidant, anti-inflammatory
and anti-cancer activities that can protect the human body, which is constantly exposed to free
radicals present externally, as well as produced internally. Antioxidants such as vitamin E,
vitamin C, RS, lignans, flavonoids, and other phenolic compounds from foods could neutralize
the environmental free radicals and slow down the process of aging (Lobo et al., 2010,
Madhujith et al., 2004, Emmons et al., 1999, Rebello et al., 2014, Jung et al., 2011). Oats as one
of the important dietary antioxidant contributors (Emmons et al., 1999, Zhang et al., 2012),
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vitamin E (tocopherols), phytic acid, phenolic compounds, and avenanthramides (Figure 3) are
the most abundant antioxidants in oat, as well as the flavonoids and sterols are present in oat
(Emmons et al., 1999). These antioxidants attenuate the DNA damage and lipid peroxidation
caused by the free radicals in the human body (Emmons et al., 1999, Xiao et al., 2015).
Table 2 Macronutrient content of whole grain oat flour and oat bran.
%, as is basis
Whole grain oat flour
10 - 17
56 - 62
4-9
11 - 17
2-7

Protein
Starch and sugars
Fat
Total dietary fiber
ß-Glucan

Oat bran
13 - 24
10 - 50
5 - 14
15 - 32
6 - 20
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Figure 3 Structure of Avenanthramide.

2.5 Wheat bran
Wheat bran is the by-product from milled refined grain production. Although refined
grains have an extended shelf life and a finer texture, refined grain foods contain solid fats,
added sugars, and sodium. Wheat bran is high in a non-digestible form of carbohydrates and
presents a high concentration of vitamins, minerals, and dietary fiber while refined grains are low
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in some of these essential nutrients (USDA, 2010). Wheat bran provides a good source of
proteins and minerals apart from being a good source of dietary fiber (Table 3). Wheat bran is
also low in saturated fat, trans-fat, mono- and oligo- saccharides, calories (H and Prakash, 2002).
Wheat bran can be used to make many food products, such as cookies, bread, cereal, pasta, and
cereal bar. Wheat bran is of relatively low fermentability, which helps to account for its relative
superiority as a fecal bulking and laxating agent (Topping and Clifton, 2001). During the
refining process of grains the bran and germ fractions are removed. Thus, most refined cereal
products have lost the protective components (Slavin, 2004).
Table 3 Chemical composition of wheat flour and wheat bran samples (H and Prakash, 2002).
Constituent (Per
100g)
Moisture (g)
Protein (g)
Fat (g)
Carbohydrate (g)
Total ash (g)
Insoluble fiber (g)
Soluble fiber (g)
Iron (mg)
Phosphorous (mg)
Calcium (mg)
Bioavailable iron
(mg)

Whole
wheat
flour
8.54±0.002
14.0±0.120
1.57±0.106
67.6
1.52±0.001
5.45
1.3
8.0±0.0
435
40
1.83

Bran fractions

Whole wheat
bran

Coarse

Medium

Fine

2.17±0.001
15.0±0.146
4.08±0.002
28.1
4.99±0.004
42.8
2.8
15.1±0.0
560
78.3

6.65±0.212
15.1±0.002
4.13±0.003
16.2
5.22±0.001
49.9
2.8
12.0
920
96

6.88±0.084
18.57±0.397
2.40±0.001
34.0
4.55±0.005
37.05
2.6
10.0
1200
96

8.23±0.003
20.3±0.282
2.79±0.006
48.7
3.48±0.001
15.2
1.3
9.5
1400
160

3.16

-

-

-

2.6 C. elegans model
C. elegans is a small, free-living (as opposed to parasitic) soil nematode widely
distributed around the world (Wood, 1988, Riddle et al., 1997). C. elegans is a multicellular
eukaryotic organism, about 1mm in length, with transparent and round shape body (Riddle et al.,
1997). C. elegans is the first animal to have its genome completely sequenced and more than 65%
of the genes relating to human disease are conserved in C. elegans (Shen et al., 2009). Wild-type
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C. elegans (N2) live for approximately 21-25 days. They grow to adult in 38-46hours after
hatching; C. elegans has a life cycle about 3 days under optimal conditions (Figure 4). C.
elegans have large brood sizes of 300 progeny per hermaphrodite when grown in an agar dish
and fed with non-pathogenic Escherichia coli (E. coli, OP50) as a standard laboratory food
source.

Figure 4 Life cycle diagram of C. elegans at 22°C.

C. elegans can be maintained in the laboratory using Nematode Growth Medium (NGM)
agar in petri dish or liquid culture fed with E. coli OP50. The pharynx is responsible for the
ingestion of bacteria by crushing the bacteria in the grinder in the terminal bulb and passing the
food into the intestine through the pharyngeal-intestinal valve through coordinated muscular
contraction (Mango, January 22, 2007). Wild type and over 3,000 mutant strains of C. elegans
are available in Caenorhabditis Genetics Center (CGC), University of Minnesota (Minneapolis,
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MN) at no cost to researchers at educational institutions or non-profit organizations. C. elegans
strains used in this study included: N2 Bristol (Wild type), null strains of sir-2.1(ok434)IV, daf16(mgDf50)I and daf-16(mgDf50)I;daf-2(m65) III (Table 4).
C. elegans is a convenient model system in many research fields including genomics, cell
biology, neuroscience and aging (Zheng and Greenway, 2012). It is also practical to use this
animal studying the effect of bioactive materials on lifespan, fat metabolism, and Parkinson’s
disease. The pharyngeal pumping rate (PPR) of C. elegans is negatively correlated to their
lifespan and is well accepted in the study of aging (Greer et al., 2007). Locomotion analyses
have shown that there is altered or impaired C. elegans response to exogenous insults or toxins
(Boyd et al., 2010). Using RNAi with Nile Red staining, Ashrafi et al. have reported that 305
genes are responsible for reducing body fat and 112 genes are responsible for increasing fat
storage (Ashrafi et al., 2003). C. elegans deposits fat for energy storage along its intestinal tract.
Lipid staining dyes such as Nile Red or BODIPY can be visualized directly and quantitated
photometrically in the intact and transparent animal (O'Rourke et al., 2009, Zhang et al., 2010).
C. elegans model serves as an intermediate step in research which will also reduce the number of
rodents or other higher animals required (Zheng and Greenway, 2012, WormAtlas. Altun, 2005).
Table 4 Information of C. elegans strains.
Strains
Wild type (N2)
daf-16(mgDf50)I

Gene deficient
daf-16

daf-16(mgDf50)I;
daf-2(m65)III

daf-16 and daf-2

Human homologs
Forkhead box protein
O (FOXO)

Functions
C. elegans daf-16 has a
central role in mediating
the downstream insulin
signaling pathways and is
the major target of the daf-2
pathway.
FOXO and
The C. elegans daf-2 gene
insulin/IGF-1 receptor encodes the homolog of the
mammalian insulin
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sir-2.1(ok434)IV

sir-2.1

NAD-dependent
protein deacetylase
sirtuin-1

receptor, which has
preserved ligand-binding
and tyrosine kinase
domains
The sir-2.1 transgene
functions upstream of daf16 in the insulin-like
signaling pathway and was
responsible for lifespan
extension of C. elegans

2.7 Insulin signaling pathway and related genes in C. elegans
Insulin/Insulin-like growth factor Signaling (IIS) pathway is a primary mechanism for
controlling metabolic physiology not only in humans, but also in C. elegans (Figure 5) (Van
Dyke and McCarthy, 2002). Under conditions of abundant food, the IIS pathway is active.
dauer formation-2 gene (daf-2) activates the signaling cascade represses dauer formation-16 gene
(daf-16) which codes for the Forkhead family of transcription factors (FOXO), through AGEingrelated gene-1 (age-1) and akt-1/2 (Zheng and Greenway, 2012, Wang and Tissenbaum, 2006).
Reduction in the active components of IIS pathway as in daf-2 mutants or upon decreased food
availability leads to the activation of a series of genes involved in lifespan control, stress
tolerance and protein misfolding suppression, and collectively resulting in life-span extension
(Kenyon, 2010, Lin et al., 1997). Down-regulation of insulin signaling loss of function of daf-2,
a homolog of the insulin and insulin-like growth factor (IGF) receptors in C. elegans, leads to the
phosphorylation of daf-16, causes fat accumulation in adults and glycogen production (Lin et al.,
2001, Berdichevsky et al., 2006a). C. elegans age-1 is the signaling molecule downstream from
the insulin receptor and is the homolog of human phosphatidylinositol-3-hydroxy kinase (PI3K)
(Zheng and Greenway, 2012, Lin et al., 2001). DAF-18 inhibits the age-1 downstream protein
PDK-1 which phosphorylates the SGK-1/akt-1/-2 complex that acts as an inhibitor of dauer
formation-16 gene (daf-16) (Seo et al., 2015, Zheng et al., 2013, Rizki et al., 2011). The
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functions of daf-16 in biological processes include metabolism, life span, stress responses, and
dauer formation and exit, by mediating downstream gene expression in response to
environmental and nutritional conditions (Barbieri et al., 2003). daf-16 is suppressed by daf-2
and age-1 through the SGK-1/akt-1/-2 complex (Seo et al., 2015, Zheng et al., 2013, Rizki et al.,
2011).

SGK-1/akt-1/-2 complex is the homolog of human serine/threonine protein kinase

(AKT/PKB) and regulates multiple cellular process as well as glucose metabolism. ‘Aging’ has
been reported to relate with the downstream effects of IIS pathway (Figure 5) (Benedetti et al.,
2008). Insulin resistance that is a primary component in the pathophysiology of type 2 diabetes
is a pathological condition in which cells fail to respond to normal action of the hormone insulin
(Jayaprakasam et al., 2005, Chiu et al., 2007).
Insulin-like
molecules
DAF-2 (human insulin receptor)

AGE-1

AAP-1
PI3-K

PIP2

PIP3

DAF-18

PDK-1

SGK-1

Phosphorylation
AKT-1 or
AKT-2

DAF-16

Cytosol
Nucleus
DAF-16

DNA

Figure 5 Summary of the insulin signaling pathway in C. elegans.
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Longevity

DAF-16 (FOXO transcription factor) is the major target of the DAF-2 pathway (homologue of
insulin signaling pathway in C. elegans);DAF-18 inhibits PDK-1, which phosphorylates the
SGK-1/akt-1/-2
complex;
PIP2,
phosphatidylinositol
(4,5)-bisphosphate;
PIP3,
phosphatidylinositol-3,4,5-trisphosphate
(PtdIns(3,4,5)P3);
PDK-1,
3-phosphoinositidedependent kinase 1; DAF-18, homologous to human PTEN; AKT1/2 and SGK-1, orthologs of
the serine/threonine kinase Akt/PKB. Activations are indicated by ‘→’ and inhibitions are
indicated by ‘┴’.

2.8 sir-2.1 extends lifespan
Lifespan in C. elegans is controlled by many pathways independently or overlapping
such as insulin/insulin like signaling pathway and TOR (target of rapamycin) signaling pathway
(Greer and Brunet, 2009, Mair and Dillin, 2008). sir-2.1 like proteins (sirtuins), a family of
NAD+ dependent deacetylases, is related to gene silencing, DNA repair, rDNA recombination
and aging in model organisms from E. coli to humans (Figure 6) (Wood et al., 2004, Lin et al.,
2000, Hekimi and Guarente, 2003, Landry et al., 2000). sir-2.1 repressed the expression of ER
stress genes and was responsible for lifespan extension of C. elegans induced by resveratrol
(Figure 6) (Viswanathan et al., 2005).

27

DAF-2

Nucleus

SIR-2.1

DAF-16 (FOXO)

DAF-16 (FOXO)

Longevity
FA/Lipid/AA metabolism
Detoxification

Figure 6 Regulation of DAF-16/FOXO by SIR-2.1/SIRT1 in C. elegans.
SIR-2.1 coordinate to fine-tune the transcriptional activity of DAF-16 on a distinct subset of
potential target genes. DAF-16 target genes responsive to the SIR-2.1 pathway largely overlap
with a small subset of IIS-regulated genes, and are specialized in longevity determination,
cellular defense, and lipid/fatty acid/amino acid homeostasis.

Extra expression of sir-2.1 extends the lifespan of budding yeast by 30%, apparently by
mimicking caloric restriction (Wood et al., 2004) while deletion or knockdown of the gene
shortens lifespan (Wang and Tissenbaum, 2006, Bamps et al., 2009). The lifespan of sir-2.1 null
mutant was not obviously shorter than the wild-type C. elegans N2 (Wood et al., 2004). The
extension of lifespan by elevation of sir-2.1 activity might also have a FOXO-independent
function which codes daf-16 in C. elegans (Wang et al., 2010, Berdichevsky et al., 2006a). SIR28

2.1 acts with 14-3-3 proteins to affect DAF-16 activity and life span and act in parallel to the
insulin-like pathway to regulate DAF-16 and extend life span (Figure 6) (Berdichevsky et al.,
2006b).
2.9 Gene regulation of satiety signals
The satiety signals, PYY, GLP-1, and cholecystokinin (CCK) are produced in the colon
and increase in the blood stream in response to food intake (Zhou et al., 1985, Zhou et al., 2008).
CCK that is a peptide hormone found in the central nervous system and gastrointestinal tract
plays a central role in initiating satiety and modulating food intake (Moran and Kinzig, 2004,
Gibbs et al., 1973). CCK regulates food intake by being released from enteroendocrine cells in
response to the presence of lipid or protein in the gut postprandial (Moran, 2000). Exogenous
administration of CCK decreases food intake in rats (Gibbs et al., 1973). However, mice lacking
the gene for CCK have normal body weight, body mass, and fat absorption as compared with
wild-type littermate controls, differences in longevity were not examined (Lo et al., 2008).
Food-restricted rats showed increased plasma CCK, which suggests a physiological role for CCK
in the adaptation to reduced food ingestion (Chowdhury and Rayford, 2001). Two distinct
receptor proteins, CCK1R and CCK2R, mediate the action of CCK in mice, and both receptors
play a regulatory role in the control of food intake (Chowdhury and Rayford, 2001). Two
potential homologs of CCK receptors are found in the C. elegans genome, ckr-1 and ckr-2.
RNAi knockdown of ckr-1 or ckr-2 also decreases the longevity of the eat-2 mutant significantly
but has no effect on the life span of age-1(hx546) and clk-1(e2519) mutants (Park et al., 2010).
Regarding obesity, the polymorphism of the cholecystokinin 1 receptor (CCK1R) gene may be
related to an increase in body fat content in middle-aged and elderly people (Funakoshi et al.,
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2000). CCK1R mediate the CCK-induced suppression of food intake (Peikin, 1989), and the
peripheral administration of CCK1R antagonists increased food intake (Wolkowitz et al., 1990).
2.10 Quantitative real-time PCR for DNA and mRNA analysis
PCR or the polymerase Chain Reaction is a technique for amplifying DNA. Amplifying
DNA create multiple copies of strands of DNA. Amplification of DNA is able to detect enough
DNA signal for quantification. Polymerase is a thermostable enzyme and will synthesize a
complementary sequence of bases. There are two types of PCR: conventional PCR and real-time
PCR. Conventional PCR detects the amplified DNA on agarose by an end-point analysis while
real-time PCR allows the detection of the accumulation of amplified product as the reaction
proceeds. The advantage of real-time PCR over conventional PCR is the accuracy and high
sensitivity. There are several ways to detect the fluorescent PCR product including Taqman
PCR method and SYBER green method.
2.10.1 Taqman real-time PCR method for C. elegans mRNA analysis
The principle of Taqman qPCR is to use a fluorogenic labeled probe to enable the
detection of a specific PCR product as it accumulates during PCR cycles. Thermus aquatic DNA
polymerase cleave fluorescence probe (TaqMan probe), which is designed to be complementary
to a specific sequence spanned by the PCR primers. The Taqman oligonucleotide probe is
constructed containing a reporter dye at its 5́ end and a quencher dye at its 3́ end (Figure 7). If
the probe is intact, the proximity of the quencher dye greatly reduces the fluorescence emitted by
the reporter dye by fluorescence resonance energy transfer (FRET) through space.

The

Quencher dyes are usually FAM (6-carboxyfluorecein) and TAMARA (6- carboxyl- tetra methyl
-rhodamin). Using DNA binding dye more DNA copies are created and florescence increases.
If the target sequence is present, the probe anneals downstream from one of the primer sites and
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is cleaved by the 5´ nuclease activity of Taq DNA polymerase as this primer is extended.
Separation of the reporter dye from the quencher dye increases the reporter dye signal.

Figure 7 The principle of Taqman real-time PCR.
(1) Reporter and the quencher dyes are in close proximity, no fluorescence signal is emitted due
to the quenching effect (black arrow in 1, 2, and 3), (2) Soon after the annealing of the TaqMan
probe and the primers, (3) the primers are extended by the DNA polymerase. As the polymerase
reaches the TaqMan probe, it uses its exonuclease activity to remove the probe one nucleotide at
the time, (4) this releases the reporter from the proximity of the quencher and allows for the
release of a fluorescence signal from the reporter.
2.10.2 SYBR green real-time PCR method for gut microbiota DNA analysis
SYBR green is another frequently used dye in RT-PCR. The SYBR Green I dye binds to
all double-stranded DNA present in the sample. During the PCR, DNA polymerase amplifies the
target sequence, or “amplicons”. The increase in fluorescence intensity is proportional to the
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amount of amplicons produced (Figure 8). The advantages of the SYBR Green method over
Taqman method is that it can be used to monitor the amplification of any double-stranded DNA
sequence; No probe is required, which reduces assay setup and running costs. The disadvantage
of SYBR green method is that this dye can bind to nonspecific double-stranded DNA sequences.
Unbound SYBR
Green-no
fluorescence

1. Reaction setup: The SYBR Green dye
fluoresces when bound to Template ds DNA

2.Template denaturation: when the DNA
denatured, the SYBR Green dye is released and the
fluorescence is drastically reduced
SYBR Green
unbound-no
fluorescence

3. Amplification: during extension, primers anneal and
PCR product generated (annealing and extension)

4. Polymerization completed: when the polymerization is complete,
the SYBR Green dye binds to the ds DNA increase in fluorescence detected
by the 7900HT system

Figure 8 The principle of SYBR Green real-time PCR.
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CHAPTER 3: SCFAS AFFECTED THE LIFESPAN AND INTESTINAL FAT
DEPOSITION IN C. ELEGANS MODEL

3.1 Introduction
The Western-style diet is high in fat and sugar, low in fiber intake that is far less than the
recommended amount for daily diets (Eaton, 2006, Simpson and Campbell, 2015). Current daily
fiber intakes are 10 to 20 grams (Eaton, 2006) lower than the national fiber recommendations, 30
to 38 grams a day for men and 25 grams a day for women between 18 and 50 years old (King et
al., 2012). The dietary fermentable carbohydrates have relatively lower energy density and
produce similar health benefits as calorie restriction. Dietary fermentable carbohydrate can
escape the digestion in small intestine and are fermentable by anaerobic bacteria in the colon
(Macfarlane and Macfarlane, 2003). There is a tight association between fermentable nondigestible carbohydrates and positive effects on host metabolism.
Diets and intestinal microbiota play important roles in maintaining the health of host,
including preventing obesity and related metabolic complications (Korpela et al., 2014). A
considerable content of microbial flora, which are about 1011- 1013 bacteria per gram content,
exist in the colon (Backhed et al., 2004, Sekirov et al., 2010). This microbial flora includes more
than 1,000 bacterial species and most of the microorganisms are saccharolytic (Henningsson et
al., 2002, Backhed et al., 2004). Firmicutes and Bacteroidetes account for more than 90% of the
bacterial population in the colon (Ley et al., 2008). Obesity is a multifactorial state, where host
genes, life style and the gut microbiota interact in a complex and largely unknown way (Everard
and Cani, 2013, Flint, 2011).

One study has reported that the abundance of Clostridium

sphenoides was decreased in obese subjects as compared to healthy controls (Korpela et al.,
2014). The “Western” style diet causes dysbiosis which affects both host GI tract metabolism
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and immune homeostasis (Sekirov et al., 2010).

In a study with mice, the microbiota

composition of mice fed with a high fat and sugar diet is associated with increase of Firmicutes
including Clostridium innocuum, Eubacterium dolichum, Catenibacterium mitsuokai and
Enterococcus spp., as well as a significant reduction in several Bacteroides spp.(Walker et al.,
2011). In contrast, low carbohydrate diets result in enriched populations of bacteria from the
Bacteroidetes phyla (Walker et al., 2011), and calorie-restricted diets prevent the growth of
Clostridium coccoides, Lactobacillus spp. and Bifidobacteria spp., which are major butyrate
producers required for colonocyte homeostasis (Santacruz et al., 2009). Complex carbohydrates
also increase the levels of beneficial Bifidobacteria spp. such as B. longum subspecies longum, B.
breve and B. thetaiotaomicron (Pokusaeva et al., 2011).
Human colonic bacteria ferment the indigestible fermentable carbohydrate to SCFAs,
mainly acetate (C2), propionate (C3), butyrate (C4) (Topping and Clifton, 2001) and gases (CO2,
CH4, and H2) (Cummings et al., 1987). SCFAs can be rapidly absorbed from the colon and can
contribute as an energy source for intestinal epithelial cells (Vinolo et al., 2011). E. ruminantium
belongs to the family Lachnospiraceae, is xylanolytic and produces mainly formic acid as well
as butyrate (Louis et al., 2004). Clostridiaceae felsineum is a pectinolytic butyrate-producer
(Rainey FA, 2009).

Bacteroidetes and Clostridial species are active degraders of dietary

polysaccharides (Korpela et al., 2014). Other SCFAs, such as propionic acid, are beneficial at
low concentrations but have neurotoxic effects in high quantities and may play a role in the
development and persistence of the symptoms of autism. Acetate: propionate: butyrate values
were similar in different regions of the large intestine (approximately 57:22:21) (Macfarlane and
Macfarlane, 2003, Cummings et al., 1987).
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SCFAs prevent colonic diseases and metabolic diseases including irritable bowel
syndrome, inflammatory bowel disease, obesity, cardiovascular disease and cancer (Wong et al.,
2006). Butyric acid is important in the prevention and treatment of diseases of the colonic
mucosa (Henningsson et al., 2002).

SCFAs have been recognized as potential mediators

involved in the effects of gut microbiota on intestinal immune function and inflammatory
processes (Vinolo et al., 2011).

Individual SCFAs may provide specific health benefits.

Butyrate is the main energy substrate for the colonocytes and is metabolized by the cells in
preference to glucose or glutamine, accounting for 70% of the total energy demand of the colonic
mucosa (Roediger, 1982, Scheppach, 1994) and has been shown to protect against damaging
inflammatory responses.
Feeding C. elegans with SCFAs showed similar effect on the nematodes as feeding with
amylose starch or fermented RS from filtered cecal contents from amylose starch fed mice
(Zheng et al., 2010, Keenan et al., 2013). The purpose of current study was to determine the
effects of SCFAs, products of fermentable fibers, on the intestinal fat deposition, insulinresistance, and lifespan using the C. elegans N2, and null mutants, sir-2.1(ok434)IV, daf16(mgDf50)I, or daf-16(mgDf50)I;daf-2(m65) III.
3.2 Materials and methods
3.2.1 E. coli OP50 culture
An E. coli pellet was inoculated into LB (Luria-Bertani) broth containing 0.2%
streptomycin. The culture was incubated at 37°C for 24 hours, and then stored at 4°C. The
enumeration of the E. coli culture was carried out using the E. coli/coliform PetrifilmTM (Cat.

#

6404, 3M Corp., Minneapolis, MN). The incubation time for the PetrifilmTM is 24 hours at 37oC
(Zheng et al., 2010, Yuan et al., 2012).
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3.2.2 C. elegans culture
The C. elegans model organism does not require approval by Institutional Animal Care &
Use Committee (IACUC). All the C. elegans strains and E. coli, OP50, which is standard
laboratory food source for C. elegans, were obtained from Caenorhabditis Genetics Center
(CGC, University of Minnesota). The four C. elegans strains used in this study included: N2
Bristol (Wild type), null strains of sir-2.1(ok434)IV, daf-16(mgDf50)I and daf-16(mgDf50)I;daf2(m65) III.
Mature gravid C. elegans were age-synchronized with a NaOH (1M) and sodium
hypochlorite solution (5.25%, 5:2 ratios) to dissolve the C. elegans body and to release the viable
eggs. Eggs were washed with S-complete solution 3 times and hatched overnight at room
temperature. The age-synchronized C. elegans were diluted to 100 animals/ml, plated in liquid
culture in 96-well plate (120μl/well, 10-15 animals) (Solis and Petrascheck, 2011) fed with E.
coli OP50 (109 cfu/ml) (Zheng et al., 2010, Yuan et al., 2012) at 20 or 15°C (daf-16 mutant) in
low temperature incubators (Fisher Scientific, Pittsburgh, PA). Thirty microliters of 5-Fluoro-2′deoxyuridine (FUDR, 0.6mM) stock solution were added to each well at L4 stage.
The effect of SCFAs on lifespan and intestinal fat deposition (IFD) of C. elegans was
tested using 96 well plate liquid culture method (Solis and Petrascheck, 2011). Sodium butyrate
was purchased from Fisher Scientific (Cat#: AAA1107936, Pittsburgh, PA). Sodium acetate
trihydrate (Cat#: S8625), sodium propionate (Cat#: P5436), and tributyrin (Cat#: 113026) were
purchased from Sigma-Aldrich, Corp. (St. Louis, MO). Control animals were fed with E. coli
(OP50) in densities of 109 (cfu/ml). The treatment groups received additional sodium butyrate
(0.3mM, 0.6mM), sodium acetate (5mM, 50mM), sodium propionate (7mM), or tributyrin
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(0.5mM, 3mM). The numbers of live animal were manually recorded every other day under an
Inverted microscope with a 4× objective (Nikon Eclipse Ti, Melville, NY, USA).
3.2.3 Resistant starch treatment and pharyngeal pumping rate
The experimental groups were fed amylose starch containing 60% RS (Hi-Maize® 260,
Ingredion Incorporated, Bridgewater, NJ). The effect of amylose starch on the pharyngeal
pumping rate of C. elegans was tested with the NGM agar culture method. The control animals
were fed with E. coli (OP50) only. One experimental group was fed with additional amylose
starch (0.5%, 1.0%, & 3.0% w/v) in addition to E. coli (OP50). Other experimental groups were
fed amylose starch (0.5%, 1.0% and 3.0%), and an additional 2% glucose to mimic the
hyperglycemia effect. The animals were examined periodically using a stereomicroscope (Nikon
SMZ1500, Melville, NY) with transmitted light. The pharyngeal pumping rate (PPR) was
recorded manually by independent observers and the animals were returned to the incubators.
3.2.4 Nile red staining for fluorescence microscopy
Lipophilic dye, Nile red, was selected to stain the intestinal fat deposition in C. elegans
and Fluorescent intensity was evaluated. To prepare the samples for taking digital images, the
animals grown in liquid culture were harvested and washed with S-Basal buffer. The sample
containing the animals was centrifuged at 2000 ×G for 20 seconds and the procedure was washed
with S-Basel buffer 2 times. The animals were fixed with paraformaldehyde (4%) solution for
30 minutes at 4oC and washed with PBS 3 times. Nile red solution (50µl) was added to the tube
containing the animals and allowed to sit for 30 minutes (Zheng et al., 2010). Ten microliters of
fluoromount-G solution (Southern Biotechnology Associates, Birmingham, AL) was applied on
the glass slide. Ten microliters of the specimen containing Nile Red stained C. elegans was
applied on to the glass slide. A cover glass was mounted on the glass slide. The slides were
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viewed with an epifluorescence microscope (Nikon Eclipse Ti) equipped with a Texas Red filter.
Fluorescent micrographs were taken with a digital camera (Andor, DU-885K). The micrographs
were analyzed using ImagePro Plus (Media Cybernetics, Inc., MD) and analyzed with NISelements AR3.22.11 software (Nikon Instrument, Melville, NY). The micrographs were Line
profiles of the optical densities of Nile Red labeled intestinal fat deposition (Arbitrary units,
percent of control) was determined for each treatment group.
3.2.5 Statistical analyses
All results were expressed as mean±s.e.m. The data for the pharyngeal pumping rate
were analyzed with ANCOVA method by SAS 9.4. Survival curves of lifespan were displayed
by binomial probabilities as surrogates for survival probabilities and the mean survival time
(mean lifespan) was estimated by Kaplan-Meier using SAS (SAS Institute Inc., USA). The data
for fluorescence intensity and quantitative real-time PCR analyzed by (SAS 9.4).

Statistical

significance was set as P≤0.05.
3.3 Results
3.3.1 Effect of sodium butyrate on the lifespan of C. elegans
The sodium butyrate at doses of 0.3 and 0.6 mM increased the lifespan of the wild type
C. elegans N2 (P<1×10-5 and P<1×10-6, respectively) compared with the E. coli OP50 only
control (Figure 9 {A}). The mean survival time was increased by 0.3 and 0.6mM sodium
butyrate to 33.8 days and 36.9 days, respectively, compared to 24.9 days of control (Figure 9 {A}
and Table 5).

Strain sir-2.1(ok434)IV lacks the sir-2.1 gene which has previously been

implicated in aging. For this strain, sodium butyrate at concentrations of 0.3 and 0.6mM mildly
decreased the lifespan compared with the E. coli OP50 fed control (Figure 9 {B} and Table 6).
Sodium butyrate at concentrations of 0.3 and 0.6mM increased the lifespan of the daf56

16(mgDf50) I (GR1307) C. elegans strain (P=7×10-5 and P=5×10-5, respectively) compared with
the E. coli OP50 fed control (Figure 9 {C}). The mean survival time was increased to 25.9 days
and 26.1 days by the treatment of 0.3 and 0.6mM sodium butyrate, respectively, compared with
the 22.0 days for the E. coli OP50 fed control (Figure 9 {C} and Table 7).

The daf-

16(mgDf50)I;daf-2(m65) III C. elegans lacks the insulin receptor and longevity pathway. In this
strain, sodium butyrate at concentrations of 0.3 and 0.6mM slightly decreased the lifespan
compared with the E. coli OP50 fed control (Figure 9 {D}). The mean survival times were
decreased to 20.9 days and 20.5 days by the 0.3 and 0.6mM sodium butyrate, respectively,
compared to the 21.7 days for the E. coli OP50 fed control (Figure 9 {D} and Table 8).
N2

A

120

1.0

Butyrate: 0mM
Butyrate: 0.3 mM
Butyrate: 0.6 mM

Estimated Binomial Probabilities as Surrogates for Survival Probabilities

120

1.0

Butyrate: 0mM
Butyrate: 0.3 mM
Butyrate: 0.6 mM

100

40

10

20

30

40

50

60

0

60

40
0 0.2 0.4 0.6 0.8 1
[mM]

20

10

20

30

A

B

Well

C

daf-16 mutant

C

40

50

60

120

1.0

Butyrate: 0mM
Butyrate: 0.3 mM
Butyrate: 0.6 mM

A

B

C

daf-16(mgDf50)I;daf-2(m65) III

D

Estimated Binomial Probabilities as Surrogates for Survival Probabilities

Estimated Binomial Probabilities as Surrogates for Survival Probabilities

120

1.0
Butyrate: 0mM
Butyrate: 0.3 mM
Butyrate: 0.6 mM

100

0.8

100

0.8

0.4

40

10

0.2

20

0 0.2 0.4 0.6 0.8 1
[mM]

0.0
0

0.6

Estimated Mean Survival Days

0.2

60
50
40
30
20
10
0

80

Fraction of alive

Estimated Mean Survival Days

0.4

IFD (%)

80
0.6

20

30

40

50

60

0.0

0

0

60

50
40
30
20
10
0

40

20

0 0.2 0.4 0.6 0.8 1
[mM]

0
10

20

30

Day
Well

A

0

Day

Day
Well

IFD (%)

50
40
30
20
10
0

0.0

0
0

0.4

0.2

20

0.0

0.6

40

Day
B

C

Well

Figure 9 Sodium butyrate modified the lifespan of C. elegans.
57

A

B

C

50

60

IFD (%)

0.2

60

80

Estimated Mean Survival Days

0.4

IFD (%)

50
40
30
20
10
0 0 0.2 0.4 0.6 0.8 1
[mM]

Fraction of alive

80

Estimated Mean Survival Days

0.6

Fraction of alive

100

0.8

0.8

Fraction of alive

sir-2.1(ok434)IV

B

Estimated Binomial Probabilities as Surrogates for Survival Probabilities

A) Lifespan survival curve, mean survival time, and IFD results of C. elegans N2; B) Lifespan
survival curve, mean survival time, and IFD results of sir-2.1(ok434)IV C. elegans; C) Lifespan
survival curve, mean survival time, and IFD results of daf-16(mgDf50) I (GR1307) C. elegans; D)
Lifespan survival curve, mean survival time, and IFD results of daf-16(mgDf50)I;daf-2(m65) III
C. elegans.
Table 5 The effect of SCFAs on the mean survival time of Bristol wild type C. elegans N2.
#
1
2
3
4
5
6
7
8

Samples
Control
Sodium butyrate
Sodium butyrate
Sodium acetate
Sodium acetate
Sodium propionate
Tributyrin
Tributyrin

(mM)
0
0.3
0.6
5
50
7
0.5
3

Mean survival days
24.9
33.8
36.9
31.7
16.8
25.3
31.1
25.4

SEM
0.914
1.056
1.173
1.627
0.607
1.112
1.122
0.735

(%)
100.0
135.3
148.0
127.1
67.5
101.4
124.7
102.0

3.3.2 Effect of sodium acetate on the lifespan of C. elegans
Sodium acetate (5mM) also significantly increased the lifespan of C. elegans N2
(P<1×10-5, Figure 10 {A}). The mean survival time was also increased to 31.7 days (Figure 10
{A} and Table 5). However, 50mM sodium acetate significantly decreased the lifespan of C.
elegans (P<1×10-5, Figure 10 {A}). The mean survival time of the animals in this treatment was
decreased to 16.8 days (Figure 10 {A} and Table 5). This means that low dose of sodium acetate
can extend the lifespan of C. elegans but high dose of sodium acetate is toxic to the C. elegans.
Sodium acetate at 5mM and 50mM significantly decreased the lifespan of C. elegans strain sir2.1(ok434)IV (P=0.004 and P<0.001, Figure 10 {B}). The mean survival times were decreased
to 20.0 days and 12.9 days, respectively, compared to the 28 days of control group (Figure 10 {B}
and Table 6).

Sodium acetate at 5 and 50mM significantly (P=3.9×10-3 and p=1.1×10-4,

respectively) increased the lifespan of the daf-16(mgDf50) I (GR1307) C. elegans strain (Figure
10 {C}). The mean survival time was increased to 26.1 days and 24.9 days, respectively for the
two concentrations used while the mean survival time for control is 22.0 days (Figure 10 {C}
58

and Table 7). Sodium acetate at 5mM mildly decreased the lifespan of daf-16(mgDf50)I;daf2(m65) III C. elegans (Figure 10 {D}).

Sodium acetate at 50mM significantly decreased

(P=0.0008) the lifespan of this strain (Figure 10 {D}). The mean survival times were decreased
to 19.8 days and 15.1days, respectively, for the sodium acetate treatments (Figure 10 {D} and
Table 8), compared to the control of 21.7 days.
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Figure 10 Sodium Acetate modified the lifespan of C. elegans.
Experimental group received additional sodium acetate (5, 50mM). The control group obtained
standard laboratory food OP50 only (n=6). A) Lifespan survival curve, mean survival time, and
IFD results of C. elegans N2; B) Lifespan survival curve, mean survival time, and IFD results of
sir-2.1(ok434)IV C. elegans; C) Lifespan survival curve, mean survival time, and IFD results of
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daf-16(mgDf50) I (GR1307) C. elegans; D) Lifespan survival curve, mean survival time, and
IFD results of daf-16(mgDf50)I;daf-2(m65) III C. elegans.

Table 6 The mean survival times of different SCFAs on sir-2.1(ok434)IV C. elegans.
#
1
2
3
4
5
6
7
8

Treatment
Control
Sodium butyrate
Sodium butyrate
Sodium acetate
Sodium acetate
Sodium propionate
Tributyrin
Tributyrin

(mM)
0
0.3
0.6
5
50
7
0.5
3

Mean survival days
28.1
26.2
27.5
20.0
12.9
13.0
17.7
28.2

SEM
1.5
1.4
1.9
1.4
0.3
1.0
1.4
1.3

(%)
100.0
93.4
98.2
71.5
45.9
46.2
63.0
100.5

3.3.3 Effect of sodium propionate on the lifespan of C. elegans
The lifespan of C. elegans N2 treated with 7mM sodium propionate did not have
significant difference compared with the control (P=0.7794, Figure 11 {A}). The C. elegans
strain sir-2.1(ok434)IV lifespan was significantly decreased by the treatment of 7mM sodium
propionate compared to the E.coli OP50 fed control (P<0.001, Figure 11 {B}). However, the
lifespan of the strain daf-16(mgDf50) I (GR1307) C. elegans with the treatment of 7mM sodium
propionate was 24.4 days (Figure 11 {C} and Table 7), not significantly different from that of
the control (P=0.08775, Figure 11 {C}). The C. elegans strain daf-16(mgDf50)I;daf-2(m65) III
lifespan was mildly increased by the treatment of 7 mM sodium propionate compared to the
E.coli OP50 fed control (Figure 11 {D}).
Table 7 The mean survival times of different SCFAs on daf-16(mgDf50) I (GR1307) C. elegans.
#
1
2
3
4

Treatment
Control
Sodium butyrate
Sodium butyrate
Sodium acetate

(mM)
0
0.3
0.6
5

Mean survival days
22.0
25.9
26.1
26.1
60

SEM
0.829
0.827
0.707
0.494

(%)
100.0
117.4
118.4
118.5

5
6
7
8

Sodium acetate
Sodium propionate
Tributyrin
Tributyrin

50
7
0.5
3

24.9
24.4
25.0
24.3

N2

A
1.0

113.1
110.8
113.3
110.3

sir-2.1(ok434)IV

B

Estimated Binomial Probabilities as Surrogates for Survival Probabilities

0.931
0.704
0.967
0.625

Estimated Binomial Probabilities as Surrogates for Survival Probabilities

120

1.0

120
Propionate: 0mM

Propionate: 0mM

Propionate: 7mM

60

20
10
0
0

2

4

6

8

10

40

0.6

0.4

50

80

40
30

60

20
10
0
0

2

0.2

0

0.0
30

40

A

50

0

0.0

60

0

10

20

30

40

50

60

Day
B

Well

A

B

daf-16(mgDf50)I;daf-2(m65) III

daf-16 mutant

C

D

Estimated Binomial Probabilities as Surrogates for Survival Probabilities

1.0

Estimated Binomial Probabilities as Surrogates for Survival Probabilities

140

1.0

140

Propionate: 0mM

Propionate: 0mM

Propionate: 7mM

Propionate: 7mM

120

120
Estimated Mean Survival Days

0.4

100

40

Fraction of alive

0.6

0.8
50

30

80

20
10

60

0
0

2

4

6

8

10

[mM]

IFD (%)

Estimated Mean Survival Days

Fraction of alive

0.8

0.6

0.4

50

100

40
30

80

20

60

10
0
0

40

2

4

6

8

10

[mM]

0.2

0.2

10

20

30

40

50

0

0.0

0

0.0

0

60

10

20

30

A

40

50

60

Day

Day
Well

40
20

20

0

40

20

Day
Well

10

IFD (%)

20

8

0.2

20

10

6

[mM]

[mM]

0

4

IFD (%)

Estimated Mean Survival Days

30

Fraction of alive

0.4

80

IFD (%)

Estimated Mean Survival Days

Fraction of alive

0.6

0.8

50
40

100

Propionate: 7mM

100

0.8

B

Well

A

B

Figure 11 Sodium propionate modified the lifespan of C. elegans.
The control group obtained standard laboratory food OP50 only and experimental group received
additional sodium propionate (7mM) (n=6). A) Lifespan survival curve, mean survival time, and
IFD results of C. elegans N2; B) Lifespan survival curve, mean survival time, and IFD results of
sir-2.1(ok434)IV C. elegans; C) Lifespan survival curve, mean survival time, and IFD results of
daf-16(mgDf50) I (GR1307) C. elegans; D) Lifespan survival curve, mean survival time, and
IFD results of daf-16(mgDf50)I;daf-2(m65) III C. elegans.
3.3.4 Effect of tributyrin on the lifespan of C. elegans

61

The lower dose of tributyrin (0.5mM) significantly increased (P=0.0046, Figure 12 {A})
the lifespan but higher dose of tributyrin (3mM) did not significantly change the lifespan of C.
elegans N2 (P =1.00, Figure 12 {A}).

The mean survival time of C. elegans N2 in the

treatments with 0.5 and 3 mM tributyrin were 31.1 and 25.4 days compared to 25.7 days of
control (Figure 12 {A} and Table 5). Tributyrin at 0.5mM significantly decreased the lifespan of
sir-2.1 mutant C. elegans (P=0.0005, Figure 12 {B}). The mean survival time of the animals
was 13.0 days while it is 28 days in the control group (Figure 12 {B} and Table 6). In the daf16(mgDf50) I (GR1307) C. elegans, tributyrin (3mM) had no significant difference with the E.
coli OP50 fed control (Figure 12 {B}). The lower dosage of tributyrin (0.5mM) significantly
increased the lifespan of daf-16(mgDf50) I (GR1307) C. elegans. The mean survival time was
25.0 days. However, the high dose of tributyrin (3mM) did not significantly affect the lifespan
of C. elegans (P=0.398, Figure 12 {C}) or the mean survival time (24.3 days, Figure 12 {C} and
Table 7). The tributyrin at 0.5 and 3mM also mildly increased the lifespan of C. elegans strain
daf-16(mgDf50)I;daf-2(m65) III (Figure 12 {D}). The mean survival time of the animals for the
sodium propionate was 24.0 days (Figure 12 {D} and Table 3.4). The mean survival time for the
tributyrin (0.5 and 3mM) were 22.4 and 21.7days, respectively (Figure 12 {D} and Table 8).
Table 8 The mean survival times of different SCFAs on daf-16(mgDf50)I;daf-2(m65) III C.
elegans.
#
1
2
3
4
5
6
7
8

Treatment
Control
Sodium butyrate
Sodium butyrate
Sodium acetate
Sodium acetate
Sodium propionate
Tributyrin
Tributyrin

(mM)
0
0.3
0.6
5
50
7
0.5
3

Mean survival days
21.7
20.9
20.5
19.8
15.1
24.0
22.4
21.7
62

SEM
0.608
0.791
1.155
0.792
0.727
0.633
0.815
0.671

(%)
100.0
96.3
94.2
91.2
69.3
110.6
103.0
99.7

3.3.5 Feeding of SCFAs reduced the fluorescence intensity of Nile red positive intestinal fat
deposition of C. elegans
In this study, the SCFAs reduced the fluorescence intensity of Nile Red positive Intestinal
Fat Deposition (IFD) in C. elegans N2 (Figure 9 {A}, 10 {A}, 11 {A}, and 12 {A}). The
reduction was found in all treated animals as observed on day 5. As shown in Figure 9 {A}, the
IFD level of the wild type C. elegans N2 was significantly decreased to 75.7% and 74.9% of the
control group that were fed with only E. coli OP50 by 0.3 and 3mM sodium butyrate,
respectively, (P=0.0016 and P=0.0011, n=5). The application of 100mM sodium acetate reduced
the IFD to 80.7% (Figure 10 {A}, P < 0.05, n = 5) of the control.
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results of C. elegans N2; B) Lifespan survival curve, mean survival time, and IFD results of sir2.1(ok434)IV C. elegans; C) Lifespan survival curve, mean survival time, and IFD results of daf16(mgDf50) I (GR1307) C. elegans; D) Lifespan survival curve, mean survival time, and IFD
results of daf-16(mgDf50)I;daf-2(m65) III C. elegans.
The IFD of 0.3mM sodium propionate resulted in a reduction to 83% of the control (Figure 11
{A}, P=0.0394, n=5). Tributyrin at concentrations of 0.5 and 3mM also resulted in a reduction
to 77% and 66.3% of the control (Figure 12 {A}, P<0.05 and P<0.0001, n=5).
For the daf-16(mgDf50) I (GR1307) C. elegans strain, the effect of SCFAs on the IFD is
different from that observed on the wild type C. elegans N2. The treatment with sodium butyrate
did not significantly reduce the IFD at the concentrations of 0.3 and 0.6mM (Figure 9 {C}) in
contrast to the significant IFD reduction in wild type C. elegans N2 (Figure 9 {A}). The IFD
was slightly increased by the application of sodium acetate at the concentrations of 5 and 50mM
(Figure 10 {C}). Similar trend was observed in the treatments with sodium propionate and
tributyrin. The application of 7mM sodium propionate significantly (Figure 11 {C}, P<0.05, n=5)
increased the IFD in the daf-16 mutant. The IFD was also increased by 0.5 (P<0.05, n=5) and
3mM (P=0.122, n=5) tributyrin (Figure 12 {C}). These results demonstrated that sodium
butyrate, sodium acetate, and tributyrin regulate the C. elegans fat metabolism in a daf-16 gene
dependent way, but they modify the lifespan in a daf-16 gene in an independent way.
Sodium butyrate, sodium acetate, and tributyrin treatment did not significantly modify
the IFD in the daf-16(mgDf50)I;daf-2(m65) III double null mutants (Figure 9 {D}, 10 {D}, 11
{D}, and 12 {D}). The IFD in the treatment with 0.3 and 0.6mM sodium butyrate was 96.6%
(P=1, n=5) and 89.1% (P=0.95, n=5) (Figure 9 {D}), respectively, compared with the E. coli
OP50 fed control; 10mM sodium acetate slightly increased the IFD content to 109% (P=0.96,
n=5) compared with the E. coli OP50 fed control (Figure 10 {D}). The IFD for the treatment
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with 100mM sodium acetate was decreased to 90% of the control but the difference was not
significant (Figure 10 {D}, P=0.97, n=5). Sodium propionate at the concentration of 0.3mM
slightly increased IFD (Figure 11 {D}, P=0.0636, n=5). Tributyrin at the concentrations of 0.5
and 3mM did not significantly change the IFD (Figure 12 {D}, P=1 and P=0.88, respectively).
3.3.6 Amylose starch sustained the PPR
Amylose starch consists of 60% amylose starch and 40% amylopectin (Zheng et al.,
2010). Concentrations of 0.5, 1, and 3% amylose starch were used to feed wild type C. elegans
N2 and daf-16(mgDf50)I mutant. In the wild type C. elegans N2, the 0.5, 1, and 3% amylose
starch treatments sustained the PPR (P<0.05, Figure 13) compared with the control treated with
E. coli OP50 only. The 0.5, 1, and 3% amylose starch treatments did not significantly sustain the
PPR in the presence of 2% glucose (Figure 13). In the daf-16(mgDf50)I strain, the 0.5, 1, and 3%
of amylose starch treatments increased the PPR in this strain (Figure 13). In the presence of 2%
glucose, the 0.5,1 and 3% PWB treatments also sustained the PPR in the presence of glucose
(Figure 13).
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3.4 Discussion
The mean survival times of E. coli OP50 fed control for the wild type N2 and daf16(mgDf50)I;daf-2(m65) III C. elegans were 24.9 and 21.7days, respectively. Sodium butyrate
significantly increased the lifespan of the wild type C. elegan, but it did not significantly increase
the lifespan of the daf-16(mgDf50)I;daf-2(m65) III C. elegans. The low dose of sodium acetate
and tributyrin significantly increased the lifespan of the wild type and daf-16(mgDf50)I;daf2(m65) III C. elegans, but the high dose of sodium acetate and tributyrin did not significantly
increase the lifespan, in fact, they slightly reduced the lifespan. Sodium propionate at 7mM did
not significantly increase the lifespan for both the wild type and daf-16(mgDf50)I;daf-2(m65) III
C. elegans. The effect of SCFAs on the lifespan is dependent on the insulin signaling gene daf2, but not dependent on daf-16.
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The results for the sir-2.1(ok434)IV C. elegans strain demonstrated that sodium butyrate
increased the lifespan in a sir-2.1 gene dependent way. Low dose of sodium acetate also
increased the lifespan in a sir-2.1 gene dependent way, but the high dose of sodium acetate
decreased the lifespan in both strains. Tributyrin increased the lifespan also in a sir-2.1 gene
dependent way. Sodium propionate at 7mM did not significantly increase the lifespan in both
the wild type N2 and sir-2.1(ok434)IV C. elegans strains.
Sodium butyrate can increase the lifespan and the daf-2 and sir-2.1 genes are necessary to
adjust the lifespan of C. elegans.

Sodium acetate can increase the lifespan of C. elegans but the

dosage is important. High dosage of sodium acetate is harmful to the healthspan of C. elegans.
Sodium acetate adjusts the lifespan of C. elegans in daf-2 and sir-2.1 dependent way. Tributyrin
also increases the lifespan of C. elegans in a daf-2 and sir-2.1 genes dependent way.
The lifespan of C. elegans as well as other organisms such as flies, yeast, and possibly
mammals is regulated by the insulin signaling pathway gene daf-16 as daf-16 protein plays an
important role in the regulation of insulin signaling pathway in C. elegans (Lin et al., 2001).
How the SCFAs regulate the lifespan through insulin signaling pathway is still not fully
understood. Therefore, C. elegans daf-16(mgDf50) I (GR1307) which is a strain that has a
complete elimination of daf-16 coding region was used in this study. The results from this study
indicate that the effect of SCFAs on the lifespan of C. elegans is independent of the insulin
signaling gene daf-16.
The results from this study demonstrate that sodium butyrate, low dose sodium acetate
and low dose tributyrin are beneficial in extending the lifespan of C. elegans and in the reduction
of intestinal fat deposition. Sodium butyrate has the best effect among all the SCFAs tested.
Previous studies by other researchers have also shown similar effects (Zheng et al., 2010, Zheng
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et al., 2008, Keenan et al., 2013). High dose of sodium acetate negatively affected the lifespan.
The daf-16 gene is a key factor in the insulin signaling pathway of C. elegans to regulate the
longevity gene expression, but our results demonstrated that the regulation of longevity by
SCFAs is independent on the daf-16 gene.
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CHAPTER 4: PROWASHONUPANA BARLEY DIETARY FIBER REDUCES BODY FAT
AND INCREASES INSULIN SENSITIVITY IN CAENORHABDITIS ELEGANS MODEL

4.1 Introduction
Obesity costs the US health care system over $147 billion to nearly $210 billion a year
and predisposes to diabetes which generates even higher costs (Ogden et al., 2006, Cawley J,
2012). Only limited medications are available to treat obesity, and surgical treatments are
second-line obesity treatments. Diet intervention, exercise, and lifestyle modification have been
promoted by the National Institutes of Health (NIH), the United States Department of
Agriculture (USDA), and other government institutions, but sustainable weight loss has been
elusive. In an intensive diet and behavior modification program with meal replacements, adults
lost 22.6-25.51% of their body weight temporarily, but maintained only a 5% weight loss after
3 years (Kress et al., 2006, Wadden and Frey, 1997).
Daily consumption of non-digestible fiber may offer a strategy to increase energy
expenditure and reduce body fat by stimulation of mitochondrial fat oxidation (Madhujith et al.,
2004, Chandrasekara and Shahidi, 2011, John and Shahidi, 2010). Average daily consumption
of dietary fiber in the United States is currently 3 to 10 g/day, 4 to 13 fold less than
recommended (Goldring, 2004, Anderson and Akanji, 1991).

Non-digestible carbohydrate,

fermented to SCFAs in the lower gastrointestinal tract, increases satiety hormone PYY and GLP1.

These hormones augment fat oxidation (lower respiratory quotient), elevate energy

expenditure (Zhou et al., 2006, Zhou et al., 2008, Keenan et al., 2006), and inhibit body fat
accretion in rodents (Keenan et al., 2006, Shen et al., 2009). The most efficient SCFA, butyrate,
stimulates the production of PYY, GLP-1 (Zhou et al., 2006) and prevents diet-induced insulin
resistance which is directly related to a shorter lifespan in mice, a reduced cell survival, and a
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decreased lifespan in the C. elegans model organism (Gao et al., 2009, Abate and Blackwell,
2009). A diet supplemented with β-glucans at 4g/day for 14 weeks in 7 healthy overweight and
obese subjects increased fasting PYY, GLP-1, and increased post-meal satiety in humans
(Greenway et al., 2007).

We found that fermentable carbohydrate or RS, endogenous gut

fermentation products of rodents fed RS, or the exogenous SCFA, butyrate, all reduce intestinal
fat deposition (IFD) in the wild type C. elegans (N2) (Zheng et al., 2010). The lipid oxidation
pathway including cluster differentiation transport protein (CD36), carnitine palmitoyltranferase1 (CPT-1), acetyl co-enzyme A carboxylase (ACC), and acetyl CoA synthetase ACS have been
identified using genetically manipulated C. elegans (see review (Zheng and Greenway, 2012)).
Barley is the fourth most important cultivated foodstuff, and contains 62-77% starch
(w/w) which is composed of 25-35% atypical amylose starch with 3–5% RS3 and β-glucan
(Asare et al., 2011, Vasanthan and Bhatty, 1998), a mixture that provides a distinctive amylose–
amylopectin interaction (Tang et al., 2001, Lifschitz et al., 2002, Behall et al., 2005, Rendell et
al., 2005, Dongowski et al., 2002). Barley also contains high levels of functional lipids, such as,
total phytosterols (1.2-9.6% of barley oil) and total tocotrienols (0.3-0.6% of barley oil) which
are 6-12 fold higher than in palm oil (0.05%) and 4-8 fold higher than in rice bran oil (0.08%)
(Moreau et al., 2007). The barley variety Prowashonupana (PWB) contains 17% β-glucan and
15% fermentable starch (Rendell et al., 2005). These carbohydrates delay or decrease the
absorption of dietary fats and lower the postprandial glycemic response (Lifschitz et al., 2002).
Dietary fermentable fiber such as RS is present in a variety of cereals and offers the opportunity
to reduce body fat and control body weight. We demonstrated that RS2 from corn (Ingredion
Incorporated, Westchester, Illinois, USA) induced a 23% reduction of intestinal fat deposition in
wild type C. elegans (Zheng et al., 2010). The specific PWB used in the present study has a
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lower RS content compared to high amylose corn starch, but has significantly more soluble βglucan than most other barleys, which are linked to half of the PWB fiber (Behall et al., 2005,
Rendell et al., 2005). Retrograded amylose starch, RS3, and β-glucan of PW barley provide
distinctive amylose–amylopectin and amylopectin-β-glucan interactions that increase the
viscosity and delay energy absorption in the GI tract (Asare et al., 2011, Vasanthan and Bhatty,
1998, Tang et al., 2001, Moreau et al., 2007) reducing the glycemic peak by 50%, lowering low
density lipoprotein (LDL) cholesterol in healthy humans, decreasing fat accumulation in humans
and rodents (Wursch and Pi-Sunyer, 1997), augmenting immunity by activating the dectin-1
receptor and activating multiple genetic signaling pathways, including the DAF-2/insulin-like
receptor (ILR) pathways. The details of the mechanism by which insulin-resistance is improved,
however, are unclear (Tsoni and Brown, 2008, Engelmann and Pujol, 2011).
C. elegans is a small, free-living soil nematode, a multicellular eukaryotic organism,
distributed widely around the world. C. elegans is the first animal to have its genome completely
sequenced and conserves 65% of the genes associated with human disease (Zheng and
Greenway, 2012). C. elegans daf-2, is a homolog of the insulin and insulin-like growth factor
(IGF) receptor in humans and is the only gene encoding the insulin/IGF-1 like receptor in C.
elegans (Zheng and Greenway, 2012). Decreased daf-2 signaling increases C. elegans lifespan
(Kramer et al., 2003, Koga et al., 1999) which fully depends upon daf-16 (Patel et al., 2008),
since daf-16 null mutations completely suppress the extension of lifespan by daf-2 (e1370)III
null mutant (Hertweck et al., 2004, Tissenbaum and Ruvkun, 1998, Burks et al., 2000, Yu et al.,
2010, Hunt et al., 2011). Hyperglycemia (2% glucose) causes insulin resistance in N2 and daf2(e1370)III null mutants, and reduces pharyngeal movement, a surrogate marker directly related
to lifespan (Abate and Blackwell, 2009). sir-2.1 overexpression prolongs C. elegans lifespan
74

(Frojdo et al., 2011). In fact, doubling C. elegans sir-2.1 gene number induces a 50% increase in
the lifespan that is DAF-16/FOXO dependent (Tissenbaum and Guarente, 2001, Dorman et al.,
1995), and the null mutant of sir-2.1(ok434)IV has a shorter lifespan than the N2 (Gami and
Wolkow, 2006), which recently became controversial, because RNA interference (RNAi) did not
suppress the longevity (Burnett et al., 2011). The gcy-8 gene (thermotaxis) is a subtype of
guanylyl cyclase (GCYs) which has been proven to promote fat storage and mediate satiety, as
does cck.
Two thirds of the genes associated with human diseases have homologs in C. elegans,
and the C. elegans intestine has similarities to the human gastrointestinal track (You et al., 2008).
Over 300 genes have been shown to cause a reduction in body fat when inactivated, and
inactivation of more than 100 genes has shown an increased fat storage (Ashrafi et al., 2003).
The genes governing lipid metabolism do not necessarily overlap with genes governing the aging
process (Zheng and Greenway, 2012). Not only does the C. elegans model organism offer
reduced costs when screening for bioactive substances, the translucent bodies of the worms are
convenient for analysis of intestinal fat deposition (IFD) by lipid—staining dyes. Nile red
fluorescent dye has been validated through lipid-extraction, separation with thin layer
chromatography, and quantification with gas chromatography (Ashrafi et al., 2003). Recently,
Nile red staining in vitro has been recommended as being superior to coherent anti-Stokes
Raman scattering (CARS) microscopy (Yen et al., 2010).
The goal of the current study was to determine the effects of PWB on IFD, insulinresistance, and hyperglycemia-impaired lipid metabolism using the C. elegans N2, and null
mutants, sir-2.1(ok434)IV, daf-16(mgDf50)I, or daf-16(mgDf50)I;daf-2(m65) III. Pharyngeal
pumping rate (PPR), a surrogate marker of C. elegans lifespan (Chow et al., 2006b, Finley et al.,
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2013b), was also monitored to determine effect of PWB on healthspan.
4.2 Materials and methods
C. elegans strains and their standard lab food source, Escherichia coli (E. coli, OP50,
Uracil auxotroph), were provided by the Caenorhabditis Genetics Center (University of
Minnesota, Minneapolis, MN, USA). The C. elegans model is not regulated by the Institutional
Animal Care and Use Committees (IACUC) nor does it require IACUC approval (Zheng et al.,
2013).
4.2.1 Culture of E. coli (OP50)
OP50 were cultured by the standard method described elsewhere (Zheng et al., 2010).
Briefly, 10µl± of stock E. coli solution was added to Luria Broth (LB) medium and the medium
was incubated at 37C for 48h. The OP50 were then sub-cultured in PetrifilmTM E.coli/Coliform
Count Plates (3M Corporate, MN, USA) at 37C for 24h, and the colonies of OP50 were
confirmed to be at a density of 5x108 – 5x1011cfu/ml at which time the C. elegans were allowed
to eat ad libitum.
4.2.2 Culture of C. elegans
C. elegans N2, sir-2.1(ok434)IV, daf-16(mgDf50)I, and daf-16(mgDf50)I;daf-2(m65)III
null mutants were used in this study. Each strain was age synchronized, grown on NGM agar
plates (35 mm), transferred to a new dish every other day, and stored in a low temperature
incubator (Revco Tech., Nashville, NC, USA) at 20C or 15C (daf-16(mgDf50)I;daf-2(m65)III)
throughout the experiments. Mature gravid C. elegans were transferred individually onto the
agar plates and treated with a lysis solution consisting of NaOH (1M, 500 µl, v/v) and sodium
hypochlorite solution (5.25% , 200 µl, v/v) to dissolve the C. elegans body and to release the
viable eggs. Stock solutions have been previously described in detail. One day prior to the
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experiment, 200µl of a feeding media containing E. coli was added to the agar dish.
4.2.3 Diet composition
Prowashonupana barley (PWB, Sustagrain®, Ardent Mills Corporate, Denver, CO, USA)
were powdered using a centrifugal mill with a 0.75mm sieve (Retsch ZM 200; Haan, Germany),
autoclaved at 121°C, and suspended in distilled deionized water (DDH2O, 5% w/v). Detailed
nutritional data of PWB by Ardent Mills Corporate is listed in Table 9.
Table 9 Nutritional data of Prowashonupana barley (Sustagrain® Barley1), reported on a 100g
basis.
Content
Calories
Calories from Fat
Fat
Saturated Fat
Cholesterol
Carbohydrates

Quantity (g)
390 kCal
60 kCal
6.5
1.8
0
64.3

Total Dietary Fiber

30

Beta glucan
Soluble Fiber
Protein

15
12
18

Content
Vitamin A
Vitamin C
Sodium
Calcium
Iron
Vitamin B1 (Thiamin)
Vitamin B2
(Riboflavin)
Vitamin B3 (Niacin)
Potassium
Zinc

Quantity (mg)
0 IU
0
12
33
3.6
0.6
0.3
4.6
452
2.8

1

http://www.ardentmills.com/uploads/Ardent_Mills_Sustagrain.pdf

Control animals were fed with OP50 only. The experimental groups larval stage 2 (L2)
were fed supplementary Prowashonupana barley (PWB, 0.5, 1.0, or 3.0%) that had no additives.
To create insulin resistance, two percent glucose was added to an additional group of each strain,
with and without PWB (Table 10). The dietary nutrient composition is listed in Table 11 (Feijo
Delgado et al., 2013). C. elegans were transferred to fresh dishes every other day receiving
treatment (50µl).
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Table 10 PWB diet composition
Dosage (%)
Treatments
Without glucose
With glucose
(50µl)
0 0.5 1 3
0 0.5 1 3
9
OP50 (2×10 cfu/ml, µl) 10 10 10 10
10 10 10 10
PWB (5%, µl)
0
5 10 30
0
5 10 30
Glucose (50%, µl)
0
0
0 0
2
2
2 2

Table 11 Diet ingredient composition
Nutrients
Beta-glucan
Total dietary fiber
Carbohydrate
Protein
Fat

PWB diet (mg/ml) OP50 (mg/ml)
150
300
643
180
65

7.5
37.5
5.0

PWB treatment (mg/plate)
0
0.5% 1%
3%
0.000 0.012 0.023 0.069
0.000 0.018 0.037 0.110
0.375 1.983 3.590 10.020
1.875 2.325 2.775 4.575
0.250 0.413 0.575 1.225

4.2.4 Pharyngeal movement (pumping rate, PPR)
Pharyngeal pumping rate (PPR) as a surrogate marker of C. elegans lifespan (Chow et al.,
2006a, Finley et al., 2013a, Kang et al., 2007) was also monitored for the effect of these
compounds. Animals were examined periodically using a stereomicroscope (Nikon SMZ1500,
Melville, NY) with transmitted light.

The pharyngeal pumping rate (PPR) was recorded

manually by independent observers and the animals were returned to the incubators.
4.2.5 Fluorescence microscopy
The lipophilic dye, Nile red, was selected to stain the intestinal fat deposition. Prior to
fixing the animals, an S-basal (see below) solution was added to the dish to wash the animals.
The solution containing the animals was centrifuged for 20 seconds at 805G and this procedure
was repeated twice. Animals were then fixed with 4% paraformaldehyde over 2h at 4C and
washed with phosphate buffered saline (PBS) for 5 min x 3. Nile red (50 µl) was applied to the
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specimens for 10 min. Ten microliters of Fluoromount-G (Southern Biotechnology Associates,
AL, USA) was applied to a glass slide followed by 20µl of the medium containing Nile red
stained animals. A cover glass was mounted on the glass slide. The slides were viewed with an
epifluorescence microscope (Nikon Eclipse, Ti) equipped with a Texas Red filter. Fluorescent
micrographs were taken with a digital camera (Andor, DU-885k, Concord, MA, USA). The
micrographs were analyzed using NIS elements (Nikon). Line profiles of the optical densities
(arbitrary units, % of control) of Nile red labelled IFD were determined for adult animals (larval
stage 4 [L4]).
4.2.6 Quantitative RT-PCR
4.2.6.1 Reagents
The Trizol® reagent (T9424), chloroform (C2432), and isopropanol (I9516) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Taqman PCR core kit (N8080228),
MuLV Reverse Transcriptase (N8080018), and RNase Inhibitor (N8080119) were obtained from
Life Technologies (Grand Island, NY, USA). RNase-free micro tubes and pipette tips were used
in isolating RNA and in quantitative RT-PCR.
4.2.6.2 RNA isolation
Total RNA was extracted using the Trizol® reagent as described elsewhere (Ye et al.,
2007). C. elegans samples were homogenized in 1ml Trizol® Reagent (Sigma-Aldrich, St.
Louis, MO, USA) per 50-100 mg of tissue. The samples went through 5 freeze-thaw cycles in
which they were frozen in liquid nitrogen and thawed in a 37°C water bath. The homogenized
samples were vortexed at room temperature to allow the complete dissociation of nucleoprotein
complexes. Two hundred microliters of cold pure chloroform per 1ml of Trizol® reagent were
added and the samples were vortexed for 15s before being incubated at room temperature for
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5min. The samples were centrifuged at 12,000g for 10 min at 4°C, and the top aqueous phase
was transferred to a fresh tube. A 600µl aliquot of cold isopropanol per 1ml of Trizol ® reagent
was used for the initial homogenization. The samples were then incubated at room temperature
for 10min, vortexed for 15s, and centrifuged at 12,000g for 10min at 4°C. The supernatant was
removed and the RNA pellet was washed once with 1ml cold 75% ethanol. The sample was
vortexed and centrifuged at 7,500g for 5min at 4°C. The supernatant was removed completely
and the RNA pellet was briefly air-dried. The RNA pellet was re-suspended in 0.1% diethyl
pyrocarbonate (DEPC)-treated water and stored at -80°C. The RNA concentration was analysed
with a Nanodrop® ND-1000 spectrophotometer (Wilmington, DE, USA).
4.2.6.3 Quantitative RT-PCR
The mRNA levels of ckr-1, gcy-8, cpt-1, and cpt-2 were determined using Taqman®
quantitative RT-PCR (Figure 14). The following components were added in one-step RT-PCR:
2.2µl H2O, 1µl 10× Taqman® buffer A, 2.2µl 25mM MgCl2 solution, 0.3µl 10mM dATP, 0.3µl
10mM dCTP, 0.3µl 10mM dGTP, 0.3µl 10mM dUTP, 0.05µl 20U/µl RNase inhibitor, 0.05µl
50U/µl MuLV reverse transcriptase, 0.05µl 5U/µl Amplitaq gold®, 0.25µl Taqman® probe and
primers, and 3µl 5ng/µl RNA. The PCR reaction was conducted in triplicate using a Taqman®
probe and primers set (Life Technologies, Grand Island, NY) for ckr-1(Ce02408606_m1), gcy8(Ce02456184_g1), cpt-1(Ce02440434_m1), and cpt-2(Ce02459919_g1). The mRNA signal
was normalized over a eukaryotic 18S rRNA (Hs99999901-s1) internal control. The reaction
was conducted using a 7900 HT Fast real-time PCR system (Life Technologies, Grand Island,
NY, USA). Reverse transcription was done at 48°C for 30min, and AmpliTaq gold ® activation
(denaturation) was done at 95°C for 10min. Amplification of the DNA involved 40 cycles of 15s
at 95°C and 1min at 60°C. Data was analyzed using the Sequence Detector Software (Life
80

Technologies, Grand Island, NY, USA). The relative quantification of gene expression (2-ΔΔCt)
was calculated.

C. elegans culture

Tissue Collection
Extract total DNA/RNA

DNA/RNA conc. Determined
by NanoDrop® ND-1000

qRT-PCR

Applied Biosystems 7900HT
Fast Real-Time PCR

Data analysis

Figure 14 The procedures of animal culture, DNA or RNA extraction, and qRT-PCR in C.
elegans model organism (http://www.gene-quantification.de/chemistry.html).

4.2.7 Statistical analysis
All data were presented as mean ± sem. Student t-test, analysis of variance (ANOVA)
was used for IFD, analysis of co-variance (ANCOVA) was used to compare the slopes of PPR
data, and principal component analyses (PCA) was conducted using SAS 9.4 (Cary, NC, USA).
Statistical significance was set at P≤0.05.
4.3 Results
Changes of IFD indicated by fluorescent intensity of Nile red and alterations in lifespan
suggested by reduced PPR indicating aging, with or without 2% glucose, were quantified in this
study. The IFD was reduced in N2, and null mutants of sir-2.1(ok434)IV and daf-16(mgDf50)I.
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These reductions were reversed in the presence of 2% glucose. The PPRs declined in all groups
as the animals aged. PWB treatment, however, increased the PPR in all groups compared to
their control that did not receive PWB treatment. These responses were reversed in the presence
of 2% glucose.
a

b

Figure 15 Intestinal fat deposition was significantly reduced in the C. elegans (N2) that received
the PWB (0.5% or 3%) compared to a control group.

4.3.1 Intestinal fat deposition (IFD)
Post PWB treatment, the fluorescence intensity of Nile Red was dose-dependently
reduced by 19 to 44% (0.5 or 3.0%, n=6, P<0.05) in N2 (Figure 15), by 18 to 28% (0.5, 1.0, or
3.0%, n=9, P<0.01) in daf-16(mgDf50)I (Figure 16b), or by 18 to 36% (0.5, 1.0, or 3.0%, n=9,
P<0.01) in the sir-2.1(ok434)IV (Figure 16d). The reduction in N2 or daf-16(mgDf50)I was
reversed in presence of 2% glucose (Figure 16a and 16b). In daf-16(mgDf50)I;daf-2(m65) III,
PWB did not have statistically significant effect on IFD (Figure 16c). In sir-2.1(ok434)IV, only
in presence of 2% glucose, PWB (0.5 or 3.0%) induced a 40-50% reduction of the fluorescence
intensity in a dose-dependent manor (n=3, P<0.05) (Figure 16d).
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Figure 16 IFD was reduced in mutant C. elegans.
a) N2 Fluorescence intensity of Nile red was reduced in the PWB (0.5%, 1%, or 3%) treated
animals. The fluorescence intensity of Nile red reduced by PWB treated animals was reversed in
the presence of 2% glucose. b) daf-16(mgDf50)I: The fluorescence intensity of Nile red reduced
by PWB treated animals was no different compared with control animals with or without glucose.
c) daf-16(mgDf50)I;daf-2(m65)III: Fluorescence intensity of Nile red was not reduced in the
PWB (0.5% or 3%) treated animals. PWB treatment reduced Nile red fluorescence intensity in
the presence of 2% glucose. d) sir-2.1(ok434)IV: Fluorescence intensity of IFD stained by Nile
red in animals that received the PWB (0.5%, 1%, or 3%).

4.3.2 Pharyngeal pumping rate (PPR)
The PWB treatment dose-dependently elevated the PPR in N2 (1.0 or 3.0%, P<0.05)
(Figure 17a), daf-16(mgDf50)I (0.5, 1.0, or 3.0%, Fig. 17b), daf-16(mgDf50)I;daf-2(m65)III (0.5,
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1.0, or 3.0%, Fig. 17c), or sir-2.1(ok434)IV (3.0%, Fig. 17d) (n = 20animals/3 dishes, P<0.05)
without additional 2% glucose. In the presence of additional 2% glucose, the PWB treatment
dose-dependently elevated the PPR in N2 (0.5, 1.0, or 3.0%, P<0.05) (Figure 17e), daf16(mgDf50)I (0.5 or 1.0%, Figure 17f), daf-16(mgDf50)I;daf-2(m65)III (0.5, 1.0, or 3.0%,
Figure 17g), or sir-2.1(ok434)IV (3.0%, Figure 17h) (n = 20animals/3 dishes, P<0.05).
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1.0
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300
200
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0
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n = 20animals/3 dishes

Figure 17 PPR of C. elegans was reduced in all groups with aging.
An elevation of the PPR was observed in animals that received the PWB in a) N2 (P<0.05), b)
daf-16(mgDf50)I groups (P<0.05), c) daf-16(mgDf50)I;daf-2(m65) III (P<0.05) or d) sir2.1(ok434)IV (P<0.05). Similar results were observed in the presence of glucose in e) N2
(P<0.05), f) daf-16(mgDf50)I groups (P<0.05), g) daf-16(mgDf50)I;daf-2(m65) III (P<0.05) or
h) sir-2.1(ok434)IV (P<0.05).
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4.3.3 Lipid metabolism gene expression
PWB feeding (0.5, 1, and 3%) dose-dependently reduced mRNA expression of cpt-1 (2030%), cpt-2 (30-40%), ckr-1 (30-40%), and gcy-8 (30-50%) in N2. The reduction was observed
in daf-16 deficient mutant as cpt-1 (30%), cpt-2 20-30%, ckr-1 (40%), and gcy-8 (40%).
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Figure 18 PWB dose-dependently altered mRNA expressions of cpt-1, cpt-2, ckr-1, and gcy-8 in
the C. elegans model.
a) Reduced in N2 and was reversed by additional glucose; b) Elevated in daf-16 mutant with
reduction on cpt-1 with further augmentation by glucose; and c) Decreased in daf-16/daf-2
mutant and further reduced by glucose with an initial increase except cpt-1; d) Did not change in
sir-2.1 mutant while further reduced in presence of glucose.
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In daf-16/daf-2 mutant, cpt-1 was reduced by 30% while other three mRNA expressions
were elevated by cpt-2 (50%), ckr-1 (70-60%), and gcy-8 (80%). Although there was a 20%
reduction in gcy-8, feeding did not change the other three mRNA expressions in the sir-2.1
mutant. In presence of glucose, however, these mRNA expressions were increased in N2 by 10%
and in the mutant daf-16 by 40%, while mRNA expression was reduced in the mutant sir-2.1 by
50% after an initial increase of 30% and in the daf-16/daf-2 by 10-50% after an initial reduction
of 40-60% (P<0.05, Figure 18).
4.3.4 Principal component analyses (PCA)
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Figure 19 Principal component analyses (PCA) showed the relationships of the lipid metabolic
related mRNAs (ckr-1, cpt-1, cpt-2, and gcy-8), PPR slope, and IFD with two strong factors.
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Two factors explained the results of PCA. IFD has a strong negative effect with factor 1
in N2, while it has weak relationship with factor 1 in other strains. IFD has a strong positive
relationship with factor 2 in daf-16, daf-16/daf-2, and sir-2.1 null mutants. PPR slope has a
strong negative relationship with factor 2 in daf-16/daf-2, and sir-2.1 null mutants, but there was
a strong positive relationship with factor 1 in daf-16 mutant. IFD and PPR have an inverse
relationship in all strains. cpt-1, ckr-1, gcy-8, and cpt-2 have strong positive relationship with
factor 1 but these 4 genes have an indirect relationship with factor 2 (Figure 19).
4.4 Discussion
PWB induced significant reductions of IFD in N2 (40%) and daf-16(mgDf50)I (25%)
deficient mutants, but not in the daf-16(mgDf50)I;daf-2(m65)III deficient mutant. The PPR was
elevated with all varieties of animals fed PWB. On the contrary, reduced fluorescence intensity
and elevated PPR were detected in daf-16/daf-2(m65)III deficient mutant in the presence of an
additional 2% glucose. PWB reduced cpt-1, cpt-2, ckr-1, and gcy-8, which was reversed in sir2.1 deficient mutant suggesting that the major pathway of this effect is mediated by sir-2.1. It
appeared that glucose reversed the effect of PWB in the N2. Dissimilarly, daf-16 deficiency had
only a reduction of cpt-1 with elevations on cpt-2, ckr-1, and gcy-8, all of which had an initial
reduction. Additional glucose augmented the PWB effects to a greater degree than in N2. Thus,
daf-16 seemed to be playing an inhibitory role on lipid and glucose metabolism. PWB had
similar effects in daf-16/daf-2 mutant as in N2. Unlike N2, the effect of additional glucose in
daf-16/daf-2 mutant was eliminated by an initial increase in cpt-2, ckr-1, and gcy-8 followed by
further reduction. These findings indicated that daf-2 mediated the PWB effect but to a lesser
degree than sir-2, and facilitated glucose metabolism.
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Hyperlipidemia is often co-existent with hyperglycemia. Insulin-resistance induces
hyperglycemia in rodent diabetes due to an increased peroxisome proliferator activated receptorα (PPARα) (Hostetler et al., 2008).

Deletion of nuclear hormone receptor-49 (nhr-49), a

homologue of PPARα in C. elegans, prevents hyperlipidemia and restores insulin-sensitivity
comparable to that seen in PPARα null mice (Atherton et al., 2008). In the current study, the
PWB (3.0%) induced more than a 40% reduction in the IFD, which was daf-16 or sir-2.1
dependent since the effect was not seen in the daf-16/daf-2 mutant. The effect of reducing or not
reducing insulin sensitivity in the treatment groups described above was reversed when
decreased insulin-sensitivity was created by excessive glucose, and produced IFD reduction in
daf-16/daf-2 mutant insulin-resistance model. Since daf-16 has a central role in mediating the
downstream insulin signaling pathways and is the major target of the daf-2 pathway which
negatively regulates daf-16 (Lee et al., 2009, Kenyon et al., 1993), possibly, PWB/-glucans
indirectly affected insulin-sensitivity by affecting hyperglycemia impaired lipid metabolism and
served as a unique functional food in addition to providing a source of RS. daf-2 is the only gene
that encodes the insulin/IGF-1 like receptor in C. elegans and the genes governing lipid
metabolism do not necessarily overlap with genes governing the aging process (Zheng and
Greenway, 2012). We found that neither sir-2.1 nor daf-16 was required for the PWB diet to
reduce IFD.

Due to increased fat oxidation (with decreased RQ) and increased energy

expenditure (Zhou et al., 2008, Keenan et al., 2006, Shen et al., 2009), rodents that received RS
had significantly greater body fat reduction with continually elevated serum levels of the
hormones PYY and GLP-1 rather than peaks of these hormones in serum only after food
consumption to signal satiety (Zhou et al., 2008, Keenan et al., 2006). In agreement with the
rodent studies, the reduced IFD suggested an increased fat oxidation and increased energy
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expenditure rather than an augmented satiety or reduced food intake. Glucose appeared to
increase gcy-8 gene expression which promotes fat storage. This effect is lost in the presence of
the sir-2.1 deficient mutant or with the lack of daf-2/daf-16, which suggest that the additional
glucose induced insulin resistance is dependent on daf-2 pathway and is suppressed by sir-2.1.
The other genes do not seem to play much of a role, but the small increase in cpt-2 with glucose
is reversed in sir-2.1 deficient mutant and the lack of both daf-2/daf-16. Since cpt-2 gene
expression in the daf-16 deficient mutant did not change, the effect of glucose on cpt-2 was
thought to be through daf-2 and that sir-2.1 inhibited that effect.
Extra glucose reduces C. elegans lifespan which may be independent of insulinsensitivity and changes in body fat. As indicated by a surrogate marker of aging PPR, PWB
sustained healthspan or lifespan. However, the PPR was not increased and was reduced with
aging when an additional 2% glucose was added to all the strains tested except the daf-16/daf-2
deficient mutant. Like IFD, the effect of PWB on PPR was reversed in the daf-16/daf-2 deficient
mutant with addition of glucose suggesting an independent mechanism which may involve a
pathway outside of daf-2 or daf-2/daf-16 (Zheng and Greenway, 2012, Engelmann and Pujol,
2011), or that absence of the daf-2 promoted insulin sensitivity despite high levels of glucose.
The PPR was dose-dependently elevated in the N2, or daf-16, and daf-2/daf-16 null mutants
indicating an independency on daf-2 or daf-2/daf-16 as their absence eliminated the elevation of
PPR. The sir-2.1 gene is related to the co-regulator/genes (Kyrylenko et al., 2003) and is
partially responsible for aging in C. elegans (Lakowski and Hekimi, 1998, Houthoofd et al.,
2003). Apparently, the effect of improved healthspan or lifespan was partially dependent of sir2.1 in the present study, which was more robust than in the daf-16 mutant. The daf-2/daf-16
mutant showed increase in PPR suggested the effect was insulin/IGF-1 like receptor pathway
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dependent, which was consistently absent in daf-16 mutant.
4.5 Conclusions
Our data demonstrated that PWB reduced IFD, decreased insulin-resistance, and
improved healthspan or lifespan in the C. elegans model system which appeared to be primarily
mediated via sir-2.1, daf-16, and daf-16/daf-2. C. elegans is an attractive in vivo animal model
for initial studies of nutrition interventions prior to confirmation in higher animal species. The
identified optimal functional food components may be incorporated in various ways into daily
diet, because these are already known to have acceptability as food, and have been tested in
clinical trials. A broader test of other sources of the functional components of PWB, such as, glucan, may provide more advantageous weight loss and obesity prevention. This could result in
future improvements in public health.
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CHAPTER 5: THE EFFECT OF OATS ON LIPID METABOLISM AND INSULIN
SENSITIVITY IN THE CAENORHABDITIS ELEGANS MODEL

5.1 Introduction
Modern lifestyle-related chronic diseases, such as obesity, insulin resistance, and type II
diabetes, are major health challenges of the 21st century (Cordain et al., 2005). Changes in
dietary habits and lifestyle are among the primary causes for this undesirable development,
which is already being seen in the younger population.
An inverse connection of longevity and fat mass is characteristic of humans above 25±5%
body fat when accompanied by obesity related disease (Padwal et al., 2011). Both obesity and
aging decrease insulin sensitivity, impair the immune response, increase inflammation, weaken
the gut-bloodstream barrier, and decrease physical mobility (Padwal et al., 2011). Promotion of
dietary intervention, exercise, and lifestyle modification, including second-line obesity
treatments, to sustain weight loss has been elusive (Kress et al., 2006, Ogden et al., 2006). Even
though a direct relationship between calorie restriction and healthspan has been observed in
animal models (Ingram et al., 2002, Lee et al., 2006), controlling food intake in humans is
difficult, mainly transient, and often unsustainable as it involves multiple factors including
psychological factors.
C. elegans is well-suited to obesity studies. Lipid oxidation pathways are present in the
Caenorhabditis elegans (C. elegans) model, such as, cluster differentiation transport protein
(CD36), carnitine palmitoyltranferase-1 (CPT-1), acetyl co-enzyme A carboxylase (ACC) and
acetyl CoA synthetase (ACS). Resistant starch and short chain fatty acids reduce intestinal fat
deposition (IFD) in C. elegans demonstrating that the model can be used to evaluate bioactive
components from gut fermentation (Zheng et al., 2010, Zheng and Greenway, 2012, Finley et al.,
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2013) . C. elegans is a small, free-living soil nematode, a multicellular eukaryotic organism,
distributed widely around the world. C. elegans is the first animal to have its genome completely
sequenced and conserves 65% of the genes associated with human disease (Zheng and Greenway,
2012). C. elegans deposits fat for energy storage along its intestinal tract of its transparent body
(Hostetler et al., 2008). Thus, lipid-staining dyes such as Nile Red can be visualized directly and
quantitated photometrically in the intact C. elegans (Fei et al., 2004). Food intake and transport
in C. elegans is regulated by pharyngeal movements and relaxation in the terminal bulb of the
pharynx. The PPR declines with age due to sarcopenia, and PPR is a surrogate marker of aging
(Chow et al., 2006).
Many dietary interventions with enriched non-digestible but fermentable carbohydrates
may reinforce optimal nutrition, enhance physiological function, reduce obesity, improve
metabolic dysfunction, limit disease (Ogden et al., 2006), and produce anticancer effects in
humans (Cassidy et al., 1994, Higgins, 2004). The mechanisms of these interventions have been
reported to be due to increased mRNA expression of the GLP-1 precursor, proglucagon and PYY
in rodents (Zhou et al., 2006), improved glucose tolerance (Keenan et al., 2012, Zhou et al.,
2008), increased phase I xenobiotic metabolizing enzymes which are a hallmark of long-lived
mice (Steinbaugh et al., 2012), promotion of mitochondrial fatty acid oxidation, and increased
energy expenditure in Drosophila or adult rodents at ages analogous to 56–65 years in humans
(Keenan et al., 2006, Shen et al., 2011, Zhou et al., 2008). Consequently, fermentable dietary
fiber reduces body fat accumulation (Keenan et al., 2006, Shen et al., 2009), plasma cholesterol
and triglycerides (de Deckere et al., 1993), and insulin resistance (Gao et al., 2009) in rodents
and humans.
In addition to RS, oats (Avena sativa, Table 12) contain the soluble fermentable dietary β99

glucan fiber and the unique phytoalexins avenanthramides (avns). Avns provide safe, antioxidant, anti-inflammatory, and anti-angiogenic properties (Chen et al., 2007, Meydani, 2009,
Chu et al., 2013). Consuming oats introduces a hypocaloric intervention through caloric dilution
(Greenway et al., 2007, Saltzman et al., 2001); reduces low density lipoprotein (LDL) cholesterol
(Davy et al., 2002), body fat (Weickert et al., 2006), and coronary heart disease risk factors in
human clinical trials (Chang et al., 2013, Zhang et al., 2012); increases fasting PYY, GLP-1,
post-meal satiety, and insulin sensitivity (Huang et al., 2011); and elevates endothelium nitric
oxide production (Andersson and Hellstrand, 2012, Juvonen et al., 2009). Like resistant starch,
β-glucans are fermentable dietary fibers resistant to digestion and high-temperature cooking. An
association was detected between total fermentable phenolics, a reduction in triacylglycerols and
fewer aorta inflammatory lesions in mice (Brito et al., 2012).
Table 12 Composition of oats (Quaker® Oats)*
Content
Beta-glucan
Insoluble dietary fiber
Starch
Protein
Lipids
Moisture

Quantity (%)
4.6
7.3
60.9
13
6.6
10.3

Content
Ave 2c
Ave 2f
Ave 2p
Ave 5p
Ave total

Quantity (ppm)
5.4
8.8
5.3
1.2
20.8

Decreased daf-2 signaling, the only homolog of the human insulin and insulin-like
growth factor (IGF) receptor gene in C. elegans, increases C. elegans’ lifespan in a DAF16/FOXO-dependent manner (Hertweck et al., 2004, Patel et al., 2008, Tissenbaum and Ruvkun,
1998), which is reversed by hyperglycemia (Abate and Blackwell, 2009). Furthermore, doubling
the C. elegans sir-2.1 gene number increases lifespan by 50% in a daf-16-dependent manner
(Burnett et al., 2011, Tissenbaum and Guarente, 2001). We hypothesized that oat consumption
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would reduce IFD, improve insulin resistance created by added glucose (2%) to the C. elegans
feeding media, improve hyperglycemia-impaired lipid metabolism, and increase healthspan
through daf-16 and/or sir-2.1 pathway(s). A number of genes in C. elegans have been proven to
promote fat storage and mediate satiety, for example, guanylyl cyclases (GCYs) and the CCK
receptor. The objectives of this study were to quantify IFD by the fluorescence intensity of Nile
red staining, to evaluate healthspan by counting PPR, and to determine the genetic pathway(s)
using daf-16 and/or sir-2.1 deficient mutants.
5.2 Methods and materials
C. elegans strains and their standard lab food source Escherichia coli (E. coli, OP50,
Uracil auxotroph) were obtained from the Caenorhabditis Genetics Center (University of
Minnesota, Minneapolis, MN). The C. elegans model does not require Institutional Animal Care
and Use Committees (IACUC) regulation or approval (Zheng et al., 2013).
5.2.1 Culture of E. coli (OP50)
OP50 were cultured by the standard method described elsewhere (Zheng et al., 2010).
Briefly, approximately 10µl of stock E. coli solution was added to media and incubated at 37C
for 24h. The OP50 were then sub-cultured in PetrifilmTM (3M Corporate, St. Paul, MN) at 37C
for 24h, and the colonies were confirmed to be at a density of 5×108 – 5×1011 cfu/ml and the C.
elegans were allowed to eat ad libitum.
5.2.2 Culture of C. elegans
C. elegans wild type (N2), and null mutants sir-2.1(ok434)IV, daf-16(mgDf50)I, and daf16(mgDf50)I;daf-2(m65)III were used in this study (Table 1). They were grown on Nematode
Growth Media (NGM) agar plates (35mm), and stored in a low-temperature incubator (Revco
Tech., Nashville, NC) at 20°C or 15C (daf-16(mgDf50)I;daf-2(m65)III). C. elegans were age101

synchronized. Mature gravid C. elegans were transferred individually onto the agar plates and
treated with a NaOH (1M) and sodium hypochlorite solution (5.25%, 5:2 ratio) solution to
dissolve the body and release viable eggs (Zheng et al., 2010). One day prior to the experiment,
200µl of a feeding media containing E. coli was added to the agar dish.
5.2.3 Diet composition
Oats (Quaker® Oats instant flakes, PepsiCo Inc., Chicago, IL, Table 12) were powdered
using a centrifugal mill with a 0.75mm sieve (Retsch ZM 200; Haan, Germany), autoclaved at
121°C, and suspended in distilled deionized water (DDH2O, 5% w/v).
Control C. elegans were fed with OP50 only. The experimental groups were fed OP50
supplemented with 0.5%, 1.0%, or 3.0% oats at the larval stage L2 (Table 13). Two percent
glucose was added to an additional group of each strain with the oats. The dietary nutrient
composition is listed in Table 14 (Feijo Delgado et al., 2013). C. elegans were transferred to
fresh dishes every other day receiving treatment (50µl).
Table 13 Oats treatment composition
Volume (50µl)
Dosage (%)
Treatments
Without glucose
With glucose
Dose (%)
0 0.5 1 3
0 0.5 1 3
9
OP50 (2×10 cfu/ml, µl) 10 10 10 10
10 10 10 10
Oats (5%, µl)
0
5 10 30
0
5 10 30
Glucose (50%, µl)
0
0
0 0
2
2
2 2

Table 14 Diet ingredient composition
Nutrients
Beta-glucan
Insoluble dietary fiber
carbohydrate
Protein
Lipids

Oat diet (mg/ml) OP50 (mg/ml)
0.046
0.073
0.609
0.130
0.066

7.5
37.5
5.0
102

Oat treatment (mg/plate)
0
0.5% 1%
3%
0.000 0.012 0.023 0.069
0.000 0.018 0.037 0.110
0.375 0.527 0.680 1.289
1.875 1.908 1.940 2.070
0.250 0.267 0.283 0.349

5.2.4 Pharyngeal movement (pumping rate, PPR)
C. elegans were examined periodically using a stereomicroscope (Nikon SMZ1500,
Melville, NY) with transmitted light. The PPR was recorded manually by independent observers
then were returned to the incubators (Finley et al., 2013, Zheng et al., 2014).
5.2.5 Fluorescence microscopy
Lipophilic dye, Nile red, was used to stain for intestinal fat deposition (IFD) (Zheng et al.,
2010). S-basal solution was added to the dish to wash the C. elegans. The solution containing
the C. elegans was centrifuged for 20s at 805g and this procedure was repeated twice. C.
elegans were then fixed with 4% paraformaldehyde over 2h at 4C and washed with PBS for
5min x 3.

Nile red (50µl) was applied to the specimens for 10min.

Ten microliters of

Fluoromount-G (Southern Biotechnology Associates, Birmingham, AL) was applied to a glass
slide followed by 20µl of the medium containing Nile red stained C. elegans. A cover glass was
mounted on the glass slide, and the slides were viewed with an epifluorescence microscope
(Nikon Eclipse, Ti) equipped with a Texas Red filter. Fluorescent micrographs were taken with
a digital camera (Andor, DU-885k) and were analyzed using Nikon-Elements (version 3.22.11).
Optical densities (arbitrary units, % of control) of Nile red labeled IFD were determined for adult
C. elegans (larvae stage 4).
5.2.6 Reagents
Trizol® reagent (T9424), chloroform (C2432), and isopropanol (I9516) were purchased
from Sigma-Aldrich (St. Louis, MO). Taqman PCR core kit (N8080228), MuLV Reverse
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Transcriptase (N8080018), and Ribonuclease (RNase) Inhibitor (N8080119) were obtained from
Life Technologies (Grand Island, NY). RNase free micro tubes and pipette tips were used in
RNA isolation and quantitative RT-PCR.
5.2.7 RNA isolation
Total RNA was extracted using the Trizol® reagent as described elsewhere [66].
C.elegans samples were homogenized in 1ml Trizol® Reagent per 50-100 mg of tissue. Samples
went through 5 freeze-thaw cycles in which they were frozen in liquid nitrogen and thawed in a
37°C water bath. The homogenized samples were vortexed at room temperature to allow the
complete dissociation of nucleoprotein complexes.

Two hundred microliters of cold pure

chloroform was added and the samples were vortexed for 15s and incubated at room temperature
for 5min. The samples were centrifuged at 15,616G for 10 min at 4°C, and the top aqueous
phase was transferred to a fresh tube. A 600µl cold isopropanol was used for the initial
homogenization, and the samples were incubated at room temperature for 10min, vortexed for
15s, and centrifuged at 15,616G for 10min at 4°C. The supernatant was removed and the RNA
pellet was washed once with 1ml cold 75% ethanol. The sample was vortexed and centrifuged at
6,100G for 5min at 4°C. The supernatant was removed completely and the RNA pellet was
briefly air-dried. The RNA pellet was re-suspended in 0.1% diethyl pyrocarbonate (DEPC)treated water and stored at -80°C. The RNA concentration was analyzed with a Nanodrop® ND1000 spectrophotometer (Wilmington, DE).
5.2.8 Quantitative RT-PCR
The mRNA levels of ckr-1, gcy-8, cpt-1, and cpt-2 were determined using Taqman®
quantitative RT-PCR. The following components were added in one-step RT-PCR: 2.2µl H2O,
1µl 10× Taqman® buffer A, 2.2µl 25mM MgCl2 solution, 0.3µl 10mM dATP, 0.3µl 10mM
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dCTP, 0.3µl 10mM dGTP, 0.3µl 10mM dUTP, 0.05µl 20U/µl RNase inhibitor, 0.05µl 50U/µl
MuLV reverse transcriptase, 0.05µl 5U/µl Amplitaq gold®, 0.25µl Taqman® probe and primers,
and 3µl, 5ng/µl RNA. The PCR reaction was conducted in triplicate using a Taqman ® probe and
primer set (Life Technologies, Grand Island, NY) for Cholecystokinin receptor homolog (ckr-1,
Ce02408606_m1), guanylyl cyclase-8 (gcy-8, Ce02456184_g1), carnitine palmitoyltranferase-1
(cpt-1, Ce02440434_m1), and carnitine palmitoyltranferase-2 (cpt-2, Ce02459919_g1). The
mRNA signal was normalized over a eukaryotic 18S rRNA (Hs99999901-s1) internal control.
The reaction was conducted using a 7900 HT Fast real-time PCR system (Life Technologies).
Reverse transcription was added at 48°C for 30min, and AmpliTaq gold ® activation
(denaturation) was performed at 95°C for 10min. Amplification of the DNA involved 40 cycles
of 15s at 95°C and 1min at 60°C. Data were analyzed using the Sequence Detector Software
(Life Technologies, Carlsbad, CA, USA). The relative quantification of gene expression (2-ΔΔCt)
was calculated.
5.2.9 Statistics
All data were presented as means ± SEM. Student t-tests and ANOVA were used for
IFD, and ANCOVA was used to compare the slopes of PPR data (SAS 9.4).

Statistical

significance was set at P≤0.05. Principal component analyses (PCA) was performed to cluster
the factors of the oats results (SAS 9.4). Power analyses were performed to predict the sample
size to achieve 80% power for PPR (minimum n=7) and IFD (n=5) with statistical significance
as 0.05.
5.3 Results
5.3.1 Intestinal fat deposition (IFD)
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Oat feeding reduced IFD by 30% (0.5% and 1.0%) in the N2 strain (P<0.05), and the
addition of glucose to the oats increased IFD. IFD decreased by 17% in response to 0.5% oats
and 37% in response to 1.0% oats in the daf-16(mgDf50)I, and increased with glucose treatment
compared to the group that did not receive glucose (P<0.05). The daf-16(mgDf50)I;daf-2(m65)
III showed a similar dose-dependent reduction in IFD in response to oat feeding as well as in the
presence of glucose (P<0.05).

IFD was mildly lower following oat (0.5% and 1.0%)

consumption in the sir-2.1(ok434)IV (P>0.05) (Figure 20).

Figure 20 Nile Red staining of the intestinal fat deposition in C. elegans post Oat feeding in the
absence or presence of 2% glucose.
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5.3.2 Pharyngeal pumping rate (PPR)
The PPRs declined in all groups as the C. elegans aged. The oat treatment (0.5%, 1.0%,
or 3%) increased the PPR in N2, daf-16, and sir-2.1 mutants (n=24 C. elegans/3dishes, P<0.0010.05). The PPR in N2 was increased in oat group (0.5%, 1.0%, or 3%) in presence of glucose
(P<0.005-0.03). This increase persisted in the presence of glucose at a low dose in daf-16 or daf16/daf-2 mutant (P<0.05) (Figure 21).

Figure 21 Oat feeding affected pharyngeal pumping rate, a surrogate marker of lifespan in C.
elegans.
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5.3.3 Lipid metabolism gene expression
Oat feeding (0.5% and 1%) increased the mRNA expression of ckr-1, gcy-8, cpt-1, and
cpt-2 in the C. elegans N2, and sir-2.1 and daf-16 deficient strains (P<0.01). Additional glucose
further increased these mRNA expressions in N2 and sir-2.1. In the daf-16 deficient strain, ckr-1
and gcy-8 were increased after oat feeding (P<0.01). All four genes tested were elevated in
response to glucose treatment alone, and oat consumption in the presence of glucose significantly
reduced mRNA expression of the four genes (P<0.01). Oat feeding with glucose reduced mRNA
expression of all four genes in daf-16/daf-2 deficient strains (P<0.01). Oats (0.5%) plus glucose
increased cpt-1 and cpt-2 (P<0.01, Figure 22).
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Figure 22 Oat feeding altered gene expression of ckr-1, gcy-8, cpt-1, and cpt-2 by qRT-PCR in
C. elegans.
5.3.4 Principal component analysis (PCA)
PCA analyses revealed two theoretical strong factors that played important roles in the
relationship of the components that were tested in this study (Figure 23, Table 15). Inverse
relationship between the IFD and the PPR was detected in N2, daf-16/daf-2 and sir-2.1 mutants.
The PPRs were strongly and positively related to the two factors in the three strains. By contrast,
109

the IFDs were strongly and positively related to the factor 1 in the N2 and the daf-16/daf-2
double mutant, which was negatively associated in the sir-2.1 mutant. The IFD or PPR seemed
weakly related to the ckr-1, cpt-1, cpt-2, and gcy-8. The ckr-1, cpt-1, cpt-2, and gcy-8 had strong
positive relationships with factor 1 N2, daf-16/daf-2 and sir-2.1 mutants. A loose but positive
relationship of the 4 genes with the factor 2 was seen in the daf-16 mutant, while the IFD was
negatively related to the factor 1 and the PPR did not have any association with either the factors
or the 4 genes.
Table 15 PCA description: factor 1 and factor 2
Relation to
factors
N2
daf16(mgDf50)I
daf16(mgDf50)I;
daf-2(m65)III
sir2.1(ok434)IV

11

24

Factor 1
ckr- gcy1
8
99
98

-20

-15

95

98

29

64

2

77

20

7

93

73

-24

64

93

87

90

99

93

-73

29

30

9

8

-17

-34

98

78

96

98

95

-89

-3

52

24

-7

PPR IFD

cpt1
100

cpt2
100

Factor 2
ckr- gcyPPR IFD
1
8
94 -90
1
15

cpt1
2

cpt2
-6

5.4 Discussion
The effect of oat consumption paired with or without 2% glucose was evaluated in the C.
elegans model by observing changes in IFD determined by the fluorescent intensity of Nile red,
alterations in healthspan indicated by PPR, and variations in selected mRNA expression
indicated by PCR in this study. The IFD was reduced in N2, and the daf-16 and daf-16/daf-2
deficient mutants. Apart from natural age-related decline of the PPR in all groups, oat treatment
sustained the PPR in N2 with or without glucose. Oat treatment also sustained the PPR in daf-16
and sir-2.1 mutants without glucose. Low dose oat treatment (0.5%) increased the PPR in the
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presence of glucose. Oat consumption increased mRNA expression of ckr-1, gcy-8, cpt-1, and
cpt-2 genes, which were greater in N2 than in the sir-2.1 mutant, and additional glucose further
increased the expression by 1.5-fold in both strains. The effects of oats on healthspan and IFD in
N2 was mediated by daf-2 and partially depended on daf-16, with and without the presence of
hyperglycemia.

Figure 23 Scatterplot of principle component analysis (PCA) showing the two strong factors in
relationships with ckr-1, cpt-1, cpt-2, gcy-8, PPR slope, and IFD.

Hyperglycemia often coexists with hyperlipidemia. In C. elegans, inactivation of over
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300 genes has been shown to reduce IFD, and inactivation of more than 100 genes to increase fat
storage (Ashrafi et al., 2003). Oat consumption significantly reduced IFD in the N2, daf-16, and
daf-16/daf-2 deficient mutants, whereas the presence of glucose increased IFD. However, oats
reduced IFD even when there was insulin resistance, as seen in the daf-16/daf-2 deficient group
and other groups with additional glucose.

Glucose did not attenuate the oat-induced IFD

reduction in the daf-16/daf-2 deficient mutant suggesting an indirect improvement in insulin
sensitivity through lipid metabolism activating other pathway(s), such as the serotonin pathway.
In rodent diabetes, hyperglycemia is associated with an increase in peroxisome proliferator
activator alpha (PPARα) activity associated with insulin-resistance (Hostetler et al., 2008). In a
C. elegans model, deletion of the nuclear hormone receptor-49 (nhr-49), a homologue of PPARα,
prevents hyperlipidemia and restores insulin-sensitivity in a manner similar to PPARα null mice
(Atherton et al., 2008).

The reduced IFD following oat consumption in the daf-16/daf-2

deficient mutant suggests that oats may improve hyperglycemia-impaired lipid metabolism.
Reduced food intake, reduced lipid metabolism, and a reduction in metabolic turn over in
N2 are associated with an extension of lifespan (Burnett et al., 2011). Unlike the N2, or daf16/daf-2 and daf-16 deficient mutants, the IFD was only mildly reduced by the same amount of
oat consumption in the sir-2.1 deficient mutant with increased mRNA expression of the four
genes similar to N2 suggesting increased lipid metabolism. The ability of both the wild type and
mutant nematodes to sustain the PPR indicates that oat consumption improved healthspan
independent of the sir-2.1 pathway which relates to the co-regulator/genes in the aging process in
C. elegans (Houthoofd et al., 2003, Kyrylenko et al., 2003). Our data is in agreement with the
literature that shows involvement of sir-2.1 in lipid metabolism has multiple factors similar to
lifespan (Burnett et al., 2011), and either a higher dose is required in the absence of the sir-2.1
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gene pathway or the sir-2.1 pathway was not critically involved in the IFD reduction.
Hyperglycemia reduced the C. elegans lifespan (Lee et al., 2009) and completely
suppressed the long lifespan of daf-2(-) insulin/IGF-1 receptor mutants in C. elegans (Ogden et
al., 2006). The daf-16 gene plays a central role in activating the downstream insulin signaling
pathways and is the major target of the daf-2 which negatively regulates daf-16 (Kenyon et al.,
1993, Lee et al., 2009). In the present study, oat feeding increased PPR and decreased IFD
which were mediated by the daf-16/daf-2 pathways. The benefit from oats’ may be attributed to
its being high in fibers, β-glucan, proteins, and unique avens.
Although activation of the CCK receptor does not change circulating triacylglycerol or
adipose tissue, it increases glucose tolerance and insulin sensitivity, and decreases liver
triacylglycerol in mice (Irwin et al., 2013, Kissileff et al., 1981). Similarly in humans, activation
of CCK pathway does not appear to play a central role in long-term energy balance but signals
postprandial satiety (Jordan et al., 2008, Kissileff et al., 1981). However, ckr-1, the analogous
gene in the C. elegans species, increased in response to oat consumption which decreased IFD in
the presence of glucose and preserved PPR, suggesting ckr-1 has potential role in the lipid
metabolism. The gcy-8 is exclusively expressed in AFD neurons and contributes to thermotaxic
behavior (Inada et al., 2006).

Increased expression of gcy-8 may indicate an increase in

metabolic rate. In the daf-16 deficient mutant, the mRNA expression of ckr-1 and gcy-8 were
increased in response to oat feeding. This effect was reversed in presence of glucose that
initially elevated cpt-1 and cpt-2 followed by a reduction when oats were added.
An elevated cpt-1 or cpt-2 suggests an augmented lipid beta-oxidation and turn-over.
Expression of all four genes was reduced in the daf-16/daf-2 deficient mutant when treated with
oats, and cpt-1 and cpt-2 expression increased nearly 2-fold with additional glucose. The
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reduced cpt-1 or cpt-2 in daf-16/daf-2 deficient mutant suggests that the C. elegans were either
unable to utilize/metabolize the nutrients from the food as seen in daf-16 deficient mutant, or
were unable to adequately down-regulate metabolic turnover as observed in the daf-16/daf-2
deficient mutant, thus reducing IFD. In the three strains N2, daf-16/daf-2 and sir-2.1 mutants,
the factor 2 of the PCA was closely related to healthspan, which is inversely related to IFD, and
the factor 1 had strong positive relationships with cpt-2, and gcy-8. The PCA data showed an
inverse relationship of the daf-16 to the IFD, cpt-1, and cpt-2.
The exclusive and unique avns in oats are fermentable polyphenols that also resist
digestion and provide health benefits. A high β-glucan concentration increases viscosity in the
GI tract, delays nutrient absorption, decreases the glycemic peak by 50%, lowers LDL
cholesterol, reduces body fat in humans and rodents (Wursch and Pi-Sunyer, 1997), counteracts
obesity-related inflammation (Meydani, 2009), and enhances immunity in C. elegans by
activating the dectin-1 receptor and DAF-2/insulin-like receptor (ILR) pathways (Engelmann and
Pujol, 2011, Tsoni and Brown, 2008). These avns, along with the β-glucan content of oats make
oats a unique food that may aid in lowering body fat and controlling body weight. Future studies
will investigate possible synergistic effects of avns and β-glucan, as well as the role of the
serotonin pathway in improving hyperglycemia-induced hyperlipidemia and increasing
healthspan.
This study had limitations as well. C. elegans have 2/3 of genes that are related human
diseases. Thus, C. elegans is utilized as a stage for use in high-through put screening to search
for nutritional interventions for health prior to confirmatory studies in higher animal models and
human clinical trials.

Compensatory pathways that exist in higher animals may be not

discovered by the present study using C. elegans. Active components of the oats extract will be
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further tested in follow up studies using higher animal species.
In conclusion, our data indicates that oats have unique properties which induce an
improvement in insulin sensitivity, reduce intestinal fat deposition, and extend healthspan in the
C. elegans model organism giving support to our study hypothesis. As part of a healthy diet oats
are an appropriate food to improve public health. Avns and β-glucan are functional food
components of oats that can be incorporated into the daily diet in various ways. C. elegans is an
attractive in vivo animal model for initial studies of nutrition interventions prior to confirmation
in higher animal species.
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CHAPTER 6: THE EFFECT OF WHEAT BRAN BYPRODUCT ON LIFESPAN AND
FAT DEPOSITION ON CAENORHABDITIS ELEGANS MODEL

6.1 Introduction
Obesity are affecting more than one-third of the adults and 17% of the youth in the U.S.
(Popkin et al., 2012). Obesity are related with chronic diseases including type II diabetes,
cardiovascular diseases, high blood pressure, high cholesterol, fatty liver disease, atherosclerosis,
hypertension, sleep apneas, and certain types of cancers (Hotamisligil et al., 1994). Obesity
related chronic diseases increasingly endanger the public health and costs more than $140 billion
to the U.S health care system.
Obesity is still a non-cure epidemic disease. Although anti-obesity drugs have been
approved by FDA and exist in the market, the side effects of these drugs and the limited weight
loss have narrowed their usage. For example, sibutramine resulted in a weight loss of 4.5 kg
after 1 year treatment compared with placebo (Arterburn et al., 2004). Sibutramine may cause
blood pressure increase, dizziness or blurred vision; back pain, dry mouth, headache, nausea, and
nervousness (Snow et al., 2005, Bray and Greenway, 2007, Greenway and Bray, 2010). Surgical
treatments are used for excessive obese patients but high cost, side effects, and weight regain
have restricted the utilization of surgery. Surgery also has potential dangers to cause mortality.
For example, early mortality rates for Roux-en-Y gastric bypass (RYGB) range from 0.3% to 1%
(Snow et al., 2005).

Safe and effective obesity treatments are in a growing demand.

Fermentable dietary fiber, RS, presents an emerging solution to obesity.
The consumption of cereals decreased dramatically in the “Western” style diet in the past
decades (Adam et al., 2001). The decreased dietary fiber intake is related with the decreasing
consumption of cereals which may be one of the reasons contributing to the development of
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health disorders (Delzenne and Cani, 2005). The dietary guidelines claim that at least half of
recommended total grain intake should be whole grains (USDA, 2005). However, less than 5
percent of Americans consume the minimum recommended amount of whole grains, which for
many is about 3 ounce-equivalents per day. On average, Americans eat less than 1 ounceequivalent of whole grains per day (USDA, 2010). The consumption of higher amounts of
dietary fiber such as whole-grain foods lower the prevalence of obesity, coronary heart disease,
type II diabetes, and certain cancers (Anderson, 2004, Hauner et al., 2012).
Wheat bran by-product (WBP) is the byproduct from milled refined grains production.
Although refined grains has extended shelf life and a finer texture, refined grain foods contain
higher solid fats, added sugars, and sodium.

WBP is high in non-digestible form of

carbohydrates. WBP is also high in vitamins, minerals, and dietary fiber while the refining
grains are low in these essential nutrients (USDA, 2010) but low in saturated fat, trans-fat, monoand oligo- saccharides, calories. WBP can be used to make many food products, such as cookies,
bread, cereal, pasta, and cereal bar. Bran, though not a whole grain, is an excellent source of
dietary fiber. Therefore, WBP can supply a good source of essential nutrient, especially dietary
fiber.
The purpose of this study is to investigate the effect of WBP on health or lifespan and fat
metabolism in C. elegans model. Pharyngeal pumping rate (PPR) as a surrogate marker of C.
elegans lifespan (Finley et al., 2013, Kang et al., 2007, Chow et al., 2006) was also monitored
for the effect of WBP. Nile red, a lipophilic dye, stained intestinal fat deposition (IFD) was also
performed by fluorescence microscope.

C. elegans is a small, free-living soil nematode,

multicellular eukaryotic organism distributed widely around the world. C. elegans is the first
animal to have its genome completely sequenced and conserves 65% of the genes associated
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with human disease (Shen et al., 2009). In C. elegans, 305 genes are responsible for reducing
body fat and 112 genes are responsible for increasing fat storage (Ashrafi et al., 2003).
Compared with a rodent model, small size, short lifespan, quick turn over, complete genetic
information and their easy maintenance in the laboratory make C. elegans a valuable animal
model while greatly reducing the time and costs required to obtain answers to research questions
(Zheng and Greenway, 2011). The nematode C. elegans has been used extensively as a model
organism for biological, neurobiology and behavioral biology research (Kuriyama and Makita,
1982). We can learn the effect of WBP on lifespan and fat deposition in C. elegans and directly
apply to more complex organisms.
6.2 Materials and methods
C. elegans strains and the standard laboratory food source Escherichia coli (E. coli, OP50,
Uracil auxotroph) were obtained from Caenorhabditis Genetics Center (CGC, University of
Minnesota, Minneapolis, MN).
6.2.1 Culture of E.coli, OP50
E. coli OP50 were cultured by the standard method described elsewhere (Zheng et al.,
2010). Briefly, 10 µl of stock E. coli solution was added into LB broth solution containing 0.2%
streptomycin and incubate at 37°C shake incubator overnight and was stored at 4 °C. The E. coli
OP50 was then sub-cultured in Petrifilm™ E.coli/Coliform Count Plates (3M Corp., St. Paul,
MN) at 37oC for 24h to confirm the concentration of E. coli OP50. Densities of 5 × 108 – 5 ×
1011 cfu/mL were selected. The animals were allowed to eat ad libitum.
6.2.2 Culture of C. elegans
C. elegans wild type (N2), and null mutants sir-2.1(ok434)IV, daf-16(mgDf50)I and daf16(mgDf50)I;daf-2(m65) III, were used in this study. C. elegans was cultured on Standard
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Nematode Growth Medium (NGM) Plates (Ø35mm) at 20°C or 15°C low temperature
incubators. C. elegans was chunked to new plates seeded with OP50 each week. In order to
obtain uniform aged C. elegans to reduce the variation in the experimental results, the mature
gravid C. elegans was collected from a NGM agar plate with 1ml deionized water into a 1.5ml
micro centrifuge tube.

C. elegans was treated with NaOH (1M) and sodium hypochlorite

solution (5.25%, 5:2 ratio) lysis solution to dissolve the C. elegans body and release viable eggs.
The eggs were allowed to hatch overnight with gentle rocking (Fisher scientific, Waltham, MA)
at room temperature. The growth of the larvae was halted at the L1 stage and spread onto OP50
pre-seeded plates.
6.2.3 Wheat bran (WBP) Preparation
WBP was supplied by Ardent Milles Corporate (Denver, CO). WBP was milled by
Retsch® ZM200 (Newtown, PA) and was sieved through a 80μm sieve, and then was
incorporated to the standard feeding medium as described by Zheng et al. (Zheng et al., 2010).
Control animals were fed with E. coli OP50 only. The experimental groups were fed with
additional WBP (containing 0.5%, 1.0%, or 3.0% WBP) in absence or presence of 2% glucose.
C. elegans was transferred to a new agar plate pre-seeded with OP50 and treatments with a worm
picker every other day under stereo microscope (Nikon, Melville, NY).
6.2.4 Pharyngeal pumping rate (PPR)
Digital images were taken with Retiga 4000R. The locomotion was monitored daily with
ImagePro Plus (Media Cybernetics, Inc., Bethesda, MD). The pharyngeal pumping rate (PPR), a
surrogate marker of lifespan, was counted every other day under a stereo microscope Nikon
SMZ-1500 (Melville, NY).
6.2.5 Nile red staining for intestinal fat deposition (IFD)
126

Lipophilic dye, Nile red (Ashrafi et al., 2003, Yen et al., 2010), was used to stain for
intestinal fat deposition (IFD). Prior to fixing the animals, the animals grown on the NGM agar
plate was washed with S-Basal buffer (1ml/plate). The solution containing the animals was
centrifuged at 2200×g for 20 seconds and this procedure was repeated twice. The animals were
then fixed with 4% paraformaldehyde solution for 30 minutes at 4oC and washed with PBS for
5min ×3. Nile red solution (50µl) was added to the specimens for 30 minutes. Ten microliters
of fluoromount-G solution (Southern Biotechnology Associates, Birmingham, AL) was applied
on a glass slide. Ten microliters of the specimen containing Nile Red stained C. elegans was
applied on to the glass slide. Then, a cover glass was mounted on the glass slide. The sample
slides were viewed with a Nikon Eclipse Ti fluorescence microscope (Nikon Instrument,
Melville, NY) equipped with a Texas Red filter. Fluorescent micrographs were taken with a
digital camera (Andor, DU-885K). The micrographs were analyzed using NIS-elements
AR3.22.11 software (Nikon Instrument, Melville, NY). Line profiles of the optical densities of
Nile Red labeled IFD (arbitrary units, % of control) were determined for each group.
6.2.6 Reagents for qRT-PCR
The Trizol® reagent (T9424), chloroform (C2432), and isopropanol (I9516) were
purchased from Sigma-Aldrich (St. Louis, MO). Taqman PCR core kit (N8080228), MuLV
Reverse Transcriptase (N8080018), and RNase Inhibitor (N8080119) were obtained from Life
Technologies (Grand Island, NY). RNase free micro tubes and pipette tips were used in RNA
extraction and quantitative RT-PCR.
6.2.7 RNA extraction
The total RNA was extracted using the Trizol® reagent as described elsewhere (Ye et al.,
2007). Briefly, 50-100 mg of C.elegans tissue was homogenized in 1ml Trizol® Reagent. The
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samples went through 5 freeze-thaw cycles repeating frozen in liquid nitrogen and thawed in a
37°C water bath. The homogenized samples were vortexed at room temperature to allow the
complete dissociation of nucleoprotein complexes. Cold pure chloroform (200µl) per 1ml of
Trizol® reagent was added and the samples were vortexed for 15s and incubated at room
temperature for 5min. The samples were centrifuged at 12,000×g for 10 min at 4°C, and the top
aqueous phase was transferred to a fresh tube. A 600µl aliquot of cold isopropanol per 1ml of
Trizol® reagent was used for the initial homogenization, and the samples were incubated at room
temperature for 10min, vortexed for 15s, and centrifuged at 12,000×g for 10min at 4°C. The
supernatant was removed and the RNA pellet was washed once with 1ml cold 75% ethanol. The
sample was vortexed and centrifuged at 7,500×g for 5min at 4°C. The supernatant was removed
completely and the RNA pellet was briefly air-dried. The RNA pellet was re-suspended in 0.1%
diethyl pyrocarbonate (DEPC)-treated water and stored at -80°C. The RNA concentration was
analyzed with a Nanodrop® ND-1000 spectrophotometer (Wilmington, DE).
6.2.8 Quantitative RT-PCR
The total RNA levels of ckr-1, gcy-8, cpt-1, and cpt-2 were determined using Taqman
quantitative RT-PCR. All experiments were conducted at least three times. The PCR reaction
was conducted in triplicates using Taqman probe and primers set for ckr-1(Ce02408606_m1),
gcy-8(Ce02456184_g1),

cpt-1(Ce02440434_m1), and

cpt-2(Ce02459919_g1)

from

Life

Technologies (Grand Island, NY). The mRNA signal was normalized over eukaryotic 18S
rRNA (4331182) internal control from Life Technologies (Grand Island, NY). The reaction was
conducted with a 7900 HT Fast real-time PCR system (Life Technologies, Grand Island, NY).
Reverse transcription was done at 48°C for 30 minutes; AmpliTaq gold activate was carried out
at 95°C for 10 minutes; Amplification conditions are: 40 cycles of 15 s at 95°C and 1 minutes at
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60°C. Post-PCR data analysis was performed using the Sequence Detector Software (Applied
Biosystems). A mean value of the duplicates was used for the analysis of relative mRNA level
of ckr-1, gcy-8, cpt-1, and cpt-2.
6.2.9 Statistical Analyses
All results were expressed as mean±sem. The data for the pharyngeal pumping rate were
analyzed with ANCOVA method by SAS 9.4. The data for IFD and qRT-PCR were analyzed by
ANOVA with Dunnett’s test to compare the effects of the treatments (SAS 9.4).

Statistical

significance was set as P≤0.05. Principle component analyses (PCA) was performed to cluster
the factors of the oats results (SAS 9.4).
6.3 Results
6.3.1 Intestinal fat deposition (IFD)
WBP feeding at 0.5%, 1% and 3% reduced IFD by 27%, 17.5%, and 28%, respectively
in the N2 strain (P<0.05), and in the presence of additional 2% glucose to the WBP also
decreased IFD by 8.7%, 20%, and 22.8%. IFD decreased by 30%, 26%, and 30% in response to
0.5%, 1%, and 3% WBP feeding in the daf-16(mgDf50)I in the absence of glucose (P<0.05).
The daf-16(mgDf50)I;daf-2(m65)III strain showed a similar dose-dependent reduction in IFD in
response to WBP treatment. In the presence of glucose, WBP feeding did not significantly affect
the IFD in the daf-16(mgDf50)I and daf-16(mgDf50)I;daf-2(m65) III mutants.

In the sir-

2.1(ok434)IV mutant, the IFD was mildly lowered by WBP feeding (0.5%, 1%, and 3%, P>0.05)
and increased by 8% and 26% by WBP (1% and 3%, P<0.05) in the presence of glucose (Figure
24).
6.3.2 Pharyngeal pumping rate (PPR)
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PPR is a surrogate maker for lifespan and is declined in all groups as the animal aged.
The WBP treatment (0.5%, 1%, or 3%) increased the PPR in N2, daf-16(mgDf50)I, and sir2.1(ok434)IV mutants (n = 18 animals/3 dishes, P<0.05). In the daf-16(mgDf50)I;daf-2(m65) III
mutant, the PPR was not significantly mediated by WBP treatment (n = 18 animals/3 dishes). In
the presence of glucose, the PPR was also persisted by 3% WBP feeding in the daf-16(mgDf50)I,
by 0.5%, 1%, and 3% PWB in sir-2.1(ok434)IV mutants (n = 18 animals/3 dishes, P<0.05)
(Figure 25).
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Figure 24 The Nile Red stained fluorescence intensity of the C. elegans intestinal fat deposition.
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Figure 25 Pharyngeal movement was sustained by the WBP treatment in C. elegans.
6.3.3 Lipid metabolism gene expression
WBP feeding at 0.5%, 1% and 3% did not significantly affect the mRNA expression of
ckr-1, gcy-8, cpt-1, and cpt-2 in the wild type C. elegans (N2) in the absence of glucose (P>0.05).
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WBP feeding (3%) increased the mRNA expression of ckr-1, gcy-8, cpt-1, and cpt-2 in the daf16(mgDf50)I mutant (P<0.05). The four mRNA expression was increased by 1% and 3% WBP
treatments in the daf-16(mgDf50)I;daf-2(m65) III mutant (P<0.05). In the sir-2.1(ok434)IV
mutant, 1% WBP feeding slightly increased these four mRNA expression in the absence of
glucose (P>0.05). In the presence of glucose, 0.5% and 1% WBP increased these four mRNA
expression in N2 (P<0.05). In the daf-16(mgDf50)I mutant, 1% WBP feeding increased mRNA
ckr-1, gcy-8, and cpt-2 expression (P<0.05). The WBP treatment did not have significantly
effect on the four mRNA expression in the daf-16(mgDf50)I;daf-2(m65) III

and sir-

2.1(ok434)IV mutants (Figure 26).
6.3.4 Principal component analysis (PCA)
Two factors were utilized in PCA test to determine the relationship of IFD, PPR, ckr-1,
gcy-8, cpt-1, and cpt-2 (Figure 27). Indirect relationship between the IFD and the PPR was
detected in N2, daf-16, and daf-16/daf-2 deficient mutants.

The PPRs were strongly and

positively related to the factor 1 in the three strains. By contrast, the IFDs were strongly and
negatively related to the factor 1 in the N2 and the daf-16/daf-2 double mutant, while it was
weakly associated with factor 1 in the daf-16 and sir-2.1 mutant. The cpt-1 and cpt-2 have
strong positive relation with PPR and strong negative relation with IFD while ckr-1 and gcy-8
are weakly associated with PPR and IFD. The ckr-1, cpt-1, cpt-2, and gcy-8 had strong positive
relationships with factor 1 in daf-16 deficient mutants. In daf-16/daf-2 double mutant, gcy-8 has
strong positive relation with PPR and strong negative relation with IFD, but another three, ckr-1,
cpt-1, and cpt-2 are weakly related to PPR and IFD. In sir-2.1 deficient mutant, the IFD was
weakly related to PPR while ckr-1, gcy-8, and cpt-1 strongly and negatively related with PPR.
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Figure 26 The effect of WBP feeding on the mRNA ckr-1, gcy-8, cpt-1, and cpt-2 expression

6.4 Discussion
The effect of WBP consumption was indicated by the fluorescence intensity of Nile Red
staining intestinal fat deposition (IFD), alterations in healthspan indicated by PPR, and variations
in selected mRNA expression determined by qRT-PCR in four strains of C. elegans model with
or without 2% glucose. The IFD was reduced in N2, and the daf-16 and daf-16/daf-2 deficient
mutants. The PPR declined with the age process of C. elegans, but the WBP treatment sustained
the PPR in N2, daf-16, and sir-2.1 deficient mutants without glucose. The PPR was also
persisted by 3% WBP in daf-16 deficient mutant and WBP (0.5, 1, and 3%) in sir-2.1 mutant.
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WBP feeding slightly increased the mRNA expression of ckr-1, gcy-8, cpt-1, and cpt-2 genes in
N2 in the absence of glucose, but it significantly increased these four genes expression with
additional glucose.

In the daf-16 and daf-16/daf-2 deficient mutants, these four mRNA

expressions were up-regulated by WBP consumption.
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Figure 27 Principal component analysis

Wheat bran as a byproduct of the milling industry has been demonstrated as an excellent
source of dietary fiber (Pruckler et al., 2015). Wheat bran rich diet that has a relatively low
glycemic-index (GI) and high fiber content has been associated with low appetite, high satiety
response, and reduced the risk of developing type 2 diabetes (Silva et al., 2015). Our data
indicate that WBP consumption has positive effect on the healthspan or lifespan in N2 but this
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effect was not mediated by daf-16 and partially mediated by daf-2. In the presence of glucose,
the effect of WBP consumption on IFD has direct relationship with daf-16 which is one of the
key factors in the insulin signaling pathway. The effects of WBP consumption on IFD were
mediated by sir-2.1 gene which is a critical factor in the aging of C. elegans and other animal
models.
C. elegans is the first animal to have its genome completely sequenced and more than 65%
of the genes relating to human disease are conserved in C. elegans (Shen et al., 2009). In C.
elegans, 305 genes are responsible for reducing body fat and 112 genes are responsible for
increasing fat storage (Ashrafi et al., 2003). Hyperglycemia often coexists with hyperlipidemia.
daf-16, daf-2, and age-1 are important factors in the insulin signaling pathway in C. elegans
(Zheng and Greenway, 2012). The decrease in the intestinal fat deposition of C. elegans is
directly indicated by the reduction of fluorescence intensity of Nile red staining which linearly
correlated with the amount of body fat with a correlation coefficient of 0.998 in a previous
publication (Chen et al., 2009).

The reduction of fluorescence intensity of intestinal fat

deposition was likely a result of a decrease in energy expenditure and muscular activity. The
current study focused on the ability of fermentable fiber and RS rich WBP to reduce IFD. WBP
consumption significantly reduced IFD in N2, daf-16, and daf-16/daf-2 deficient mutants,
whereas the presence of glucose slightly increased IFD in daf-16 and daf-16/daf-2 deficient
mutants. WBP reduced IFD even when there was insulin resistant as seen in N2 with additional
glucose. However, glucose attenuated the WBP-induced IFD reduction in the daf-16 and daf16/daf-2 deficient mutants that demonstrated that insulin signaling pathway is directly related to
the lipid metabolism. Hyperglycemia is responsible for an increase in peroxisome proliferator
activator alpha (PPARα) activity associated with insulin-resistance (Hostetler et al., 2008). The
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reduced IFD induced by WBP consumption in the daf-16/daf-2 deficient mutant suggests that
WBP may improve hyperglycemia-impaired lipid metabolism.
daf-16, age-1, daf-2, and serotonin receptors are related in regulating lifespan in C.
elegans and lipid metabolism plays an important role in longevity. The PPR as a surrogate
lifespan is directly proportional to the lifespan of C. elegans. A previous study showed that
legumes that are rich in resistant starch and dietary fibers decreased IFD and increased PPR
(Finley et al., 2013).
Resistant starch or Short-chain fatty acids reduce IFD in C. elegans (Zheng et al., 2010),
increased satiety hormones GLP-1 and PYY in rodents and humans (Zhou et al., 2008,
Greenway et al., 2007). In the presence of glucose, ckr-1, gcy-8, cpt-1, and cpt-2 are endorsed
by the WBP consumption while they are slightly increased by WBP in N2. In daf-16 and daf16/daf-2 deficient mutants, ckr-1, gcy-8, cpt-1, and cpt-2 were increased by the WBP feeding,
but the presence of glucose attenuate the effect. In the sir-2.1 null mutant, ckr-1, gcy-8, cpt-1,
and cpt-2 were least affected by the WBP consumption with or without additional glucose.
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CHAPTER 7: GUT MICROBIOTA IN WILD TYPE CAENORHABDITIS ELEGANS:
STIMULATION BY MEDIA CONTAINING DIETARY FIBER FROM
PROWASHONUPANA BARLEY

7.1 Introduction
Obesity is a rapidly increasing epidemic disease affecting a large population in developed
countries without an effective cure. Safe and effective anti-obesity diets and new innovative
treatment strategies are a pressing need and in high demand (Bray and Greenway, 2007). A
present emerging solution affecting metabolism and providing health benefits includes the use of
the dietary carbohydrate prebiotic resistant starch (RS) and its fermented products that include
short chain fatty acids (SCFAs). Dietary fermentable fibers reduce energy intake by dilution of
the energy density, increase satiety, elevate fat oxidation, reduce body fat, stimulate the growth
of beneficial bacterial microorganisms in the colon, maintain bowel health (Tachon et al., 2013),
increase gene expression of PYY and proglucagon in primary colon and cecal epithelial cells
(Zhou et al., 2008),

and lower plasma lipid levels, especially cholesterol and triglyceride

concentrations in rodent studies (Dethlefsen et al., 2007).
Previous studies support the interaction of host and host microbiota being critical for the
fitness of host organisms including development, reproduction, metabolism, immunity, and
lifespan in C. elegans, mammals, and humans (Cabreiro and Gems, 2013). In addition, altering
the microbiota through dietary changes or antibiotic usage could affect the health of the host
(Maurice et al., 2013, Ikeda et al., 2007). Foods with prebiotics, including resistant starch (RS),
stimulate the growth of beneficial bacterial microorganisms in the colon (Tachon et al., 2013).
The colon microbiota utilizes fermentable carbohydrates as an energy source and produce
SCFAs, predominantly acetate, propionate, and butyrate, among others. Increasing lines of
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evidence support the concept that the gastrointestinal (GI) tract microbiota have the capacity to
impact nutrition-related syndromes like type II diabetes, obesity, and aging (Turnbaugh et al.,
2009).
The C. elegans model organism is a practical animal model for study of human diseases.
We developed a platform using C. elegans to screen different sources of prebiotics and
pharmaceutical compounds (Zheng et al., 2010, Finley et al., 2013, Zheng et al., 2014, Zheng
and Greenway, 2012). The intestine is the largest organ in C. elegans and harbors a vast
population of symbiotic microbes (Cabreiro and Gems, 2013). These nematodes have both an
aerobic and an anaerobic metabolism and can survive under a hypoxic condition (Burnell et al.,
2005). Oxygen or “hypoxia gradient”-oxygen deprivation diffuses bidirectionally between the
intestinal tract and the external environment (Burnell et al., 2005). Zheng et al. in 2010 have
demonstrated that high amylose maize RS2, its endogenous fermentation products from cecal
contents of rodents fed, and their exogenous SCFA added to the media reduced in vivo intestinal
fat deposition (IFD) and promoted healthspan in C. elegans (Zheng et al., 2010, Zheng and
Greenway, 2012). This was also demonstrated as well with a legume (Finley et al., 2013) and
Prowashonupana barley (PWB) which consists of 17% β-glucan and 15% fermentable starch
with high amounts of complex carbohydrate (Finley et al., 2013, Rendell et al., 2005, Lifschitz et
al., 2002, O'Donnell et al., 2013). These data suggested the possibility of anaerobic bacteria in
the C. elegans intestinal tract fermenting dietary fibers.
Colonic anaerobic microbiota Bifidobacteriumgenus, Bacteroides-Prevotella group,
Lactobacilli, and Clostridia spp. are necessary for fermentation of dietary fibers in humans or
rodents (Keenan et al., 2013).

Clostridium Cluster XIVa and XIVb comprise more than 20

clostridia species and their total amounts were quantified using reported primers (Rajilic142

Stojanovic et al., 2007). Bacteroides-Prevotella group primers were used to enumerate the
Bacteroides-Prevotella group including Prevotella and Porphyromonas spp. Bacteroides spp.
that are anaerobic Gram-negative bacillus bacteria (Duncan et al., 2003). Bifidobacteriumgenus
primers were used to quantify Bifidobacterium spp. that are classified under phylum
Actinobacteria (Bartosch et al., 2004), a strictly Gram-positive anaerobic branched rod producing
lactic and acetic acid but not CO2 (Van der Meulen et al., 2006). Lactobacillus spp. primers were
quantified from the genus Lactobacillus under phylum Firmicutes, which consume wide varieties
of carbohydrate as a fermentation energy source which grow under aerobic conditions or
intestinal anaerobic conditions (Van Dyke and McCarthy, 2002).
Although direct identification of C. elegans intestinal microbiota has not been reported,
we and others (Cabreiro and Gems, 2013) hypothesized that feeding resistant starch to C. elegans
should closely resemble the effect of colonic fermentation of prebiotics and produce
fermentation compounds in the large intestine as in rodents or in humans, by the intestinal
anaerobic microbiota.

This pilot study tested whether PWB, higher in fermentable fiber and

protein and lower in starch than other barley, would increase C. elegans intestinal anaerobic
microbiota. The alterations of the population of the four predominant intestinal bacterial DNA
were quantified by qRT-PCR including Bifidobacteriumgenus, Bacteroides-Prevotella group,
Lactobacillus spp., and Clostridium Cluster XIVa and XIVb in wild type C. elegans treated by
PWB.
7.2 Materials and methods
7.2.1 C. elegans preparation
Using the C. elegans model organism does not require approval by Institutional Animal
Care & Use Committees (IACUC). Wild type C. elegans (N2) and the standard laboratory food
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source Escherichia coli (E. coli, OP50) were obtained from the Caenorhabditis Genetics Center
(CGC, University of Minnesota, Minneapolis, MN). Sterile techniques were used to avoid
contamination with undesired bacteria.

The detailed procedures were previously published

(Zheng et al., 2010, Gao et al., Finley et al., 2013). An E. coli pellet was inoculated into a LB
(Luria-Bertani) broth solution containing 0.2% streptomycin, incubated at 37°C overnight, and
stored at 4°C, then plated on petrifilm (3M™ Petrifilm™ E. coli/Coliform Count Plates 6404,
3M Corp., Minneapolis, MN) at 37oC for 24h. E. coli OP50 was heat treated in a 70°C water
bath (Thermo Fisher, Waltham, MA) for 15 minutes (Houthoofd et al., 2003). Densities of
5×108 to 5×1011 colony forming units (cfu/ml) were selected and fed to the C. elegans ad libitum
(Zheng et al., 2010, Yuan et al., 2012). The mixed stages of life cycled C. elegans were cultured
in nematode growth medium (NGM) agar dish (100mm, n=5 dishes/group) in a low
temperature incubator (20oC, Fisher Scientific, Pittsburgh, PA) for one week. Milled PWB
(Ardent Milles, Denver, CO) was sieved (80μm) to a fine powder and incorporated to the
standard feeding medium as previously described (Zheng et al., 2010). Control animals were fed
the E. coli (OP50) only, the experimental group received additional PWB (1% w/v) for one week,
followed by removal of OP50 for 3 days for both groups to removal of unwanted bacteria when
nematodes were harvested for measuring intestinal bacteria. The animals then were harvested
and washed with sterilized M9 buffer x5 to remove any external bacteria (Montalvo-Katz et al.,
2013), and total material of 30±5mg/dish (7×103~8×103 C. elegans) was recovered.

To

differentiate the intestinal anaerobic bacterial DNA from extra-intestinal C. elegans’ DNA, the
supernatant of the last wash was also saved for DNA extraction. Both negative DNA results of
the supernatant and the aerobic experimental condition would support the DNA extracted from
the nematodes as being of intestinal origin.
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7.2.2 Anaerobic bacteria culture
Five bacteria were cultured individually overnight and serial dilutions were made for
analysis of four genera of bacteria: Lactobacillus plantarum strain ATCC 4163, Clostridium
coccoides strain ATCC 29236, Bacteroides fragilis strain ATCC 23745, Bifidobacterium longum
strain ATCC 15708, E. coli strain ATCC 25922, and all were used to construct standard curves
for four genera and the E.coli strain was used for the total bacterial (16S universal) domain
standard curve (Keenan et al., 2013, Senevirathne, 2010).
Five culture and quantification conditions were used to determine the total cfu/ml. Luria
Broth (Difco Laboratories, Detroit, Michigan, USA) was used to grow total E. coli aerobically at
37°C for 24 hrs.

de Man-Rogosa-Sharpe Agar (MRS agar, Difco Laboratories, Detroit,

Michigan, USA) was used to culture Lactobacillus plantarum. Brewer Modified Thioglycollate
medium (TMBM plates, BD Diagnostic Systems, Sparks, Maryland) was used to culture
Bifidobacterium longum and Bacteroides fragilis and determine bacterial counts. A reinforced
Clostridial agar (Oxoid, Basingstoke, UK) was used for Clostridium coccoides counts. The MRS
agar plates were anaerobically incubated at 30°C for 48 hr, while the TMBM agar plates and the
reinforced Clostridial agar plates were anaerobically incubated at 37°C for 3 to 4 days in a
chemically generated anaerobic system using an anaerobic box GasPak™ EZ (Mitsubishi Gas
Chemical America, Inc., New York, NY).
Serial dilutions of each bacterial extraction were prepared for generating standard curves
and DNA quantification (ng/l). Ct values from the C. elegans were quantified from the
standard curves of high efficiency (E=10-1/slope, >90%) to determine the amount of DNA
extraction (ng/l). The intestinal bacterial DNA (cfu/ml) was determined (slope/efficiency) with
the following criteria: Bacteroides-Prevotella group (-3.38/97.6%), Bifidobacteriumgenus (145

3.60/90%), and Clostridium Cluster XIVa and XIVb (-3.43/96%), Lactobacillus spp. (-3.39/97%),
and 16S universal (-3.48/94%).

7.2.3 Genomic DNA extraction
The method of modified rapid isolation of genomic DNA from human and animal stool
samples by Keenan et al has been described elsewhere (Keenan et al., 2013). Briefly, in this
study the DNA of each bacterial serial dilution or the intestinal bacteria from the C. elegans was
isolated using the QIAamp DNA Stool Mini Kit (QIAGEN, Valencia, CA) and quantified
(Nanodrop® ND-1000 spectrophotometer, Wilmington, DE).
7.2.4 Quantitative real-time PCR (qRT-PCR) assay
DNA extracted from the C. elegans was used for qRT-PCR assay (2ng/µl). The primers
were obtained from Integrated DNA Technologies (Coralville, IA): Bacteroides Prevotella
group (Bartosch et al., 2004), Bifidobacterium genus (Bartosch et al., 2004), Clostridium Cluster
XIVa and XIVab (Matsuki et al., 2002) and Lactobacillus spp. (Haarman and Knol, 2006) (Table
16).

Primers targeting universal hypovariable regions of the16S ribosomal DNA gene

(16SrDNA) were used to estimate the total bacterial counts (Belenguer et al., 2006). The
amplification thresholds (Ct) of all samples were analyzed in duplicate (SYBR® Green PCR
master mix, ABI PRISM 7900 Sequence Detection System, and SDS 2.4, Life Technologies,
Grand Island, NY). The amount of bacterial DNA extraction from the anaerobic culture was
quantified by qRT-PCR (Ct), which was correlated with the bacteria populations (cfu/ml), and
standard curves were generated (Figure 28). The amount of unknown DNA of intestinal bacteria
extracted from the C. elegans was quantified using the standard curves.
7.2.5 Statistical analysis
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Data were presented as mean±sem. A factorial arrangement of the treatments (two-way
ANOVA) with Dunnett’s test was used to compare the effects of the treatments (SAS 9.4).
Statistical significance is set as P0.05.
Table 16 Quantitative real-time PCR primers used to profile intestinal samples
Targeted bacteria
16S Universal Primers

Sequence of oligonucleotide
F – GTGSTGCAYGGYYGTCA
R- ACGTCRTCCMCNCCTTCCTC

Bacteroidetes
group
F – GAAGGTCCCCCACATTG
including Prevotella and
R- GGGTGGTAATGCCGGATG
Porphyromonas
F – GGGTGGTAATGCCGGATG
Bifidobacterium spp.
R- TAAGCCATGGACTTTCACACC
Clostridium Cluster IV
(Clostridium
leptum
F – TTACTGGGTGTAAAGGG
subgroup,
includes
R- TAGAGTGCTCTTGCGTA
Faecalibacterium
prausnutzii)
Clostridium Cluster XIVa
and XIVb (Clostridium F – AAATGACGGTACCTGACTAA
coccoides – Eubacterium R- CTTTGAGTTTCATTCTTGCGAA
rectale subgroup)
Lactobacillus spp.

F – TGGATGCCTTGGCACTAGGA
R- AAATCTCCGGATCAAAGCTTACTTAT

Reference
(Belenguer et
al., 2006)
(Bartosch et
al., 2004)
(Bartosch et
al., 2004)
(Van Dyke
and
McCarthy,
2002)
(Matsuki
al., 2002)

et

(Haarman
and
Knol,
2006)

7.3 Results
The anaerobic bacteria (cfu/ml) were detected in the extracted total genomic DNA by
specific primer sets that represented several genera, which indicated that it was of intestinal
origin (Table 16) because no bacterial DNA was detected in the last wash supernatant of the
nematodes done before DNA extraction of the nematodes.
The amount of unknown DNA of intestinal bacteria extracted from the C. elegans was
quantified by qRT-PCR, and the populations of the target bacteria were calculated using the
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standard curves. The bacterial counts in control group were: Bacteroides-Prevotella group (0.56
cfu/ml), Bifidobacteriumgenus (1.4 cfu/ml), or Clostridium Cluster XIVa and XIVb (6.26x104
cfu/ml), or Lactobacillus spp. (4.01x108 cfu/ml). Lactobacillus spp. had the highest population
which was 7.16×108-fold higher than Bacteroides-Prevotella group, or 2.86×108–fold more than
Bifidobacteriumgenus, or 6.4x103-fold greater than Clostridium Cluster XIVa and XIVb, while
the population of Lactobacillus spp. did not change in PWB treated group (2.21x108 cfu/ml,
P=0.2251, n=5). PWB treatment increased the bacterial counts in Bacteroides-Prevotella group
(2.64 cfu/ml, P=0.007), Bifidobacteriumgenus (3.51 cfu/ml, P<0.001), and Clostridium Cluster
XIVa and XIVb (3.96x105 cfu/ml, P=0.0353, Figure 29). Post PWB treatment, the Lactobacillus
spp. was reduced (50%) while other anaerobic bacterial species was increased in the following
order: Clostridium Cluster XIVa and XIVb (633%), Bacteroides-Prevotella group (472%), or
Bifidobacteriumgenus (250%, Figure 30).
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Figure 28 Standard curves for Lactobacillus spp., Clostridium Cluster XIVa and XIVb,
Bacteroides-Prevotella group, Bifidobacteriumgenus and E. coli (ATCC 25922).
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Figure 30 PWB (1%) treatment increased the total DNA of the tested bacteria (P<0.05). The
increase of the anaerobic bacteria was in the following order: Clostridium Cluster XIVa and XIVb
(633%) > Bacteroides-Prevotella group (472%) > Bifidobacterium genus (250%).
7.4 Discussion
We previously demonstrated that dietary fibers reduce IFD and promote healthspan in the
C. elegans model organism (Zheng et al., 2010, Finley et al., 2013), as has been shown by others
in rodents (Tachon et al., 2013) and humans (Rendell et al., 2005). The fact that “Oxygen or
‘hypoxia gradient’-oxygen deprivation diffuses bidirectionally between the intestinal tract and
the external environment” (Burnell et al., 2005) supports the hypothesis that C. elegans intestinal
tract contain anaerobic bacteria and prebiotics can alter the bacteria microbiota composition to
improve the health of the host (Burnell et al., 2005). This pilot study tested whether anaerobic
bacteria inhabited the intestine of the C. elegans and if a prebiotic, PWB can increase specific
genera of anaerobic bacteria. Four predominant intestinal bacteria normally found in humans
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and rodents were detected and quantified by qRT-PCR in wild type C. elegans by specific DNA
primer sets representing at the genus level of taxonomy. These anaerobic bacteria, except four
Lactobacillus spp., were increased in the PWB (1%) treated group. The majority of species in
the human GI tract belong to two phyla, the firmicutes and Bacteroides-Prevotella group
(Turnbaugh et al., 2006).

Lactobacillus spp., and Clostridium Cluster XIVa and XIVb are

members of phylum Firmicutes (Bell, 1969).

Bacteroides spp, Bifidobacterium spp, and

Lactobacillus spp ferment RS to produce acetate, propionate, succinate, and lactate, but not
butyrate (Sekirov et al., 2010, Haarman and Knol, 2006, Duncan et al., 2003, Louis et al., 2007,
Dethlefsen et al., 2007). Clostridium Cluster IV and Clostridium Cluster XIV are two major
bacterial genera that have species that produce butyrate (Belenguer et al., 2006, Louis et al.,
2007). The high population of Lactobacillus spp.in the present study is likely due to the survival
characteristics in both aerobic and anaerobic conditions based on the oxygen gradient mentioned
earlier.

Prebiotic intake, like type 2 RS from high-amylose maize, is directly associated with an
increase in the total bacterial population in fecal samples and their production of fermentation
products like SCFAs. SCFA’s stimulate production of gut satiety hormones, augment food
digestion and GI motility, elevate energy expenditure, promote insulin sensitivity, boost
mitochondrial function, augment drug metabolism, inhibit pathogens, produce vitamins, and
enhance the health of the host in species ranging from C. elegans, rodents, to human (Zheng et
al., 2010, Cabreiro and Gems, 2013, Keenan et al., 2013, Turnbaugh et al., 2006, Dethlefsen et
al., 2007, Wang et al., 1996, Flint, 2012). In addition, prebiotics alter the composition and
population of intestinal microbiota by enhancing the growth of beneficial bacteria which extract
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energy from polysaccharides including RS (Turnbaugh et al., 2006) and regulate host
metabolism by the xenobiotic cues perceived in the intestine (Cabreiro and Gems, 2013, Shen et
al., 2009).
Freshly isolated C. elegans from the wild often harbor diverse bacteria in their gut or
associated with their bodies (Bumbarger et al., 2013, Foll et al., 1999). To avoid extra-intestinal
bacteria contamination, we washed the animals a total of five times and performed bacteria DNA
extraction from the supernatant of the last wash from which bacterial DNA was not detected.
The control animals had reduced numbers in their anaerobic bacterial populations of CC14a &
CC14b, Bacteroides-Prevotella group, and Bifidobacteriumgenus. The animals receiving the
PWB had increases in the intestinal anaerobic bacterial number attributed to the carbohydrate
rich in RS of PWB, and to other fibers that reduced dietary energy density. Detection of the
elevated levels of DNA from the anaerobic bacteria in the PWB treated animals demonstrated
that dietary changes can alter the host-microbiota and increase subgroups of anaerobic bacterial
populations. Fermentable dietary fibers in PWB, such as RS or their fermentation products
SCFAs, can extend
lifespan and reduce intestinal fat deposition in the C. elegans model organism (Zheng et al.,
2010), and the microbiota appears to be associated with these improved health effects of
fermentable fiber in C. elegans.
7.5 Conclusions
This preliminary study demonstrated that four predominant anaerobic bacteria genera
were present in the intestine of C. elegans and there was an increase in the total bacterial
population with PWB (1%) treatment. The detected anaerobic bacterial DNA expression proved
the general concept for the first time that the C. elegans intestinal tract is inhabited by anaerobic
152

bacteria capable of fermenting dietary fibers. PWB altered the intestinal microbiota of the C.
elegans presumably by intestinal fermentation of dietary fibers. The results will be pursued with
further genomic DNA sequencing to determine the full range of different bacterial species in the
C. elegans intestine. Further mechanistic studies will also be conducted to identify genetic and
functional pathways like genetic manipulations of aging and insulin signaling pathways, the use
of various fermentable fibers and the fermentation products of those fibers. These studies will
expand research on the potential health benefits of dietary carbohydrate consumption in humans.
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CHAPTER 8: CONCLUSIONS

This study indicated that SCFAs including butyrate, low dose acetate and tributyrin
increased the lifespan of N2 and daf-16(mgDf50)I C. elegans while reduced the lifespan in the
daf-16/daf-2 deficient and sir-2.1(ok434)IV mutants. The IFD was reduced by butyrate (0.3,
0.6mM), acetate (100mM), propionate (0.3mM), and tributyrin (0.1, 1mM) in N2; and was
increased in sir-2.1 null mutant. High dose of sodium acetate or tributyrin negatively affected
the lifespan that indicate that SCFAs alter the lifespan of C. elegans is in a dose dependent way.
The insulin signaling pathway is a key factor in the regulation the lifespan of C. elegans model.
Our results demonstrated that the regulation of longevity by SCFAs is partially dependent on the
daf-16 gene and dependent on daf-2 gene. The SCFAs increased the lifespan of C. elegans was
dependent on another longevity gene, sir-2.1.
Our data demonstrated that PWB sustained the healthspan in N2, daf-16(mgDf50)I, and
daf-16(mgDf50)I;daf-2(m65)III with or without hyperglycemia.

High dose of PWB also

sustained healthspan of C. elegans in sir-2.1(ok434)IV. Additionally, the health benefits of PWB
also was indicated by the reduction of IFD and the deceleration of insulin-resistance in the C.
elegans model system which appeared to be primarily mediated via sir-2.1, daf-16, and daf16/daf-2. These effects were attenuated by hyperglycaemia on IFD in N2 or daf-16/daf-2 mutant.
The functional components of PWB including β-glucan and phenolics, may provide more
advantages in weight loss and obesity prevention.
The N2, daf-16, or sir-2.1 mutant increased the PPR following oat consumption. Oatfeeding decreased IFD in N2, and daf-16 or daf-16/daf-2 mutant with or without hyperglycaemia.
Oats also induced an improvement in insulin sensitivity. Unique component, Avns and β-glucan,
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indicate oats as a functional food can be incorporated into the daily diet in various ways
including improve the public health.
Wheat bran also sustained the heathspan in N2, sir-2.1(ok434)IV, daf-16(mgDf50)I, and
daf-16(mgDf50)I;daf-2(m65)III. This increase persisted in the presence of glucose at a low dose
in daf-16 or daf-16/daf-2 mutant. Wheat bran reduced IFD in N2, sir-2.1 or daf-16 null mutants.
Wheat bran reduced IFD in N2, and in daf-16 or daf-16/daf-2 mutants without hyperglycemia,
while hyperglycemia increased IFD in sir-2.1(ok434)IV.
The pilot study of gut microbiota in C. elegans indicated that four predominant anaerobic
bacteria genera were present in the intestine of C. elegans. The detected anaerobic bacterial
DNA expression provided evidence to indicate that the C. elegans intestinal tract is inhabited by
anaerobic bacteria capable of fermenting dietary fibers. Intestinal fermentation of dietary fibers
altered the intestinal microbiota divisions presumably.
In summary, PWB, oats, wheat bran, and SCFAs reduced the IFD and improved the
healthspan in C. elegans, and these effects were mediated by the sir-2.1, daf-2, or daf-2/daf-16
pathways. This could result in future improvements in public health. The identified optimal
functional food components may be incorporated in various ways into daily diet, because these
are already known to have acceptability as food, and have been tested in clinical trials. A
broader test of other sources of the functional components of PWB, such as, -glucan, may
provide more advantageous weight loss and obesity prevention. C. elegans is an attractive in
vivo animal model for initial studies of nutrition interventions prior to confirmation in higher
animal species.
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